PROTECTIVE STRATEGIES AGAINST ACETAMINOPHEN INDUCED HEPATOTOXICITY

BY

Chieko Saito

Submitted to the Graduate Degree Program in Pharmacology, Toxicology, and Therapeutics and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy

Dissertation Committee

Hartmut Jaeschke, Ph.D. (Chair)

Curtis D. Klaassen, Ph.D.

Bryan L. Copple, Ph.D.

John D. Robertson, Ph.D.

John G. Wood, Ph.D.

Date defended: January 19, 2010
The dissertation committee for Chieko Saito certifies that this is the approved version of the following dissertation:

PROTECTIVE STRATEGIES AGAINST ACETAMINOPHEN INDUCED HEPATOTOXICITY

Dissertation Committee

Hartmut Jaeschke, Ph.D. (Chair)

Curtis D. Klaassen, Ph.D.
Bryan L. Copple, Ph.D.
John D. Robertson, Ph.D.
John G. Wood, Ph.D.

Date approved: __________________________
ACKNOWLEDGEMENTS

I would like to thank my mentor, Dr. Hartmut Jaeschke, for his guidance during my graduate training. I would also like to thank the members of my lab, Dr. Mary Lynn Bajt, Dr. Anup Ramachandran, Dr. Min Yang, Huimin Yan, Margitta Lebofsky, Clarence Williams, Mitch McGill, Dr. Ji-Young Hong, Dr. Tadashi Hasegawa, Dr. Jayanthika Wijeweera, and Cathleen Cover for teaching me experimental techniques for correcting my English, and being good partners for discussion. I would like to acknowledge the members of my dissertation committee Dr. Curtis Klaassen, Dr. Bryan Copple, Dr. John Robertson, and Dr. John Wood. I am grateful to you for all your contributions. I would like to thank Dr. Antonio Artigues, Dr. Maria Villar, and Dr. Partha Krishnamurthy at the University of Kansas Medical Center for giving me good advice and helping me with my experiments. I would like to acknowledge Dr. Claudia Zwingmann at the Centre hospitalier de l’Universite de Montreal for helping me with NMR experiments. I would like to thank all other Pharm/Tox faculty members and office staff for their support. I would like to show my gratitude to my colleagues at the University of Kansas Medical Center: Thank you, Noriko Esterly, Kaori Nakamoto, Dr. Masayuki Fukui, Dr. Jennifer (Yukun) Zhang, Dr. Baljit Kaur, Yi Weaver, Dr. Benjamin Weaver, Dr. Mary Shawgo, Shary Shelton, Dr. Chunshan Gui, Emily Zhou, Dr. Bo Kong, Dr. Manimaran Rengasamy, Miyuki Shimizu, and Mariko Nishibe for being good friends and helping me a lot.
I would like to express thanks to faculties and friends at the University of Arizona: Dr. Ronald Lynch, Dr. Heddwen Brooks, Dr. Nathan Cherrington, Dr. Andrew Lickteig, Dr. Adonna Rometo, Gabrielle Halko, David Halko, and Lillie Hansen who encouraged me and with whom I had much fun.

Last, but not least, I appreciate my family for their support.
ABSTRACT

Acetaminophen (APAP) is a widely used analgesic, which is safe at therapeutic levels. APAP is mainly conjugated with glucuronic acid and sulfate to form water-soluble, nontoxic metabolites. Only a small portion of APAP is metabolized by P-450 isoenzymes, thereby forming the reactive metabolite $N$-acetyl-$p$-benzoquinone imine (NAPQI). NAPQI can react with sulfhydryl groups such as GSH. After APAP overdose, hepatic GSH is dramatically reduced, and NAPQI is able to bind to cellular proteins including mitochondrial proteins. This protein binding results in mitochondrial dysfunction and reactive oxygen species formation. This chain of events eventually leads to necrotic cell death of hepatocytes. My goal was to investigate the mechanisms and signaling pathways of APAP-induced cell necrosis in the liver, and to identify therapeutic approaches to prevent liver failure. Three protective strategies were investigated in detail:

1) Glutathione (GSH) and $N$-acetylcysteine (NAC)
2) Metallothionein (MT)
3) C-jun N-terminal kinase (JNK) inhibitor

1) Both in humans and in experimental animals, NAC is used as an antidote against APAP-induced liver injury. The doses of NAC that are being used clinically and experimentally are higher than needed for re-synthesis of hepatic GSH levels. In fact, our laboratory demonstrated that lower doses of GSH are highly effective in protecting against APAP toxicity. Therefore, I
investigated whether there is a difference between the efficacy of NAC and GSH in protecting against APAP hepatotoxicity. Our data indicate that the amino acids supplied with the delayed treatment of the same dose of GSH or NAC are used for the re-synthesis of hepatic glutathione at similar levels, which protect against APAP-induced reactive oxygen species and peroxynitrite in the mitochondria. However, excess amino acids derived from GSH also serve as energy substrates for the Krebs cycle, which results in better protection against APAP hepatotoxicity than NAC treatment. Thus, the optimal protection by delayed GSH or NAC treatment involves the combination of two mechanisms, which are the accelerated recovery of mitochondrial GSH levels and the support of the mitochondrial bioenergetics.

2) Metallothionein (MT) expression attenuates APAP-induced liver injury; however, the mechanism of this protection remains incompletely understood. To address this issue, mice were treated with ZnCl₂ for three days to induce MT. Twenty-four hours after the last dose of zinc, the animals received 300 mg/kg APAP. We found that the protective effect of MT in vivo was not due to the direct scavenging of reactive oxygen species and peroxynitrite. In addition, zinc treatment had no effect on the early GSH depletion kinetics after APAP administration, which is an indicator of the metabolic activation of APAP to its reactive metabolite NAPQI. MT was able to effectively trap NAPQI by covalent binding. We conclude that MT scavenges some of the excess NAPQI after GSH depletion and prevents covalent binding to cellular proteins,
which is the trigger for the propagation of the cell injury mechanisms through mitochondrial dysfunction and nuclear DNA damage.

3) C-jun N-terminal kinase (JNK) has been suggested to contribute to APAP-induced liver injury. The postulated mechanism of JNK involvement was the promotion of mitochondrial Bax translocation, which triggers mitochondrial outer membrane pore formation and results in the release of intermembrane proteins such as apoptosis inducing factor (AIF) and endonuclease G (EndoG). However, it was reported that Bax-deficient mice were only temporally protected against APAP-induced liver injury (Bajt et al., 2008). In contrast, the protective effect of a JNK inhibitor was observed consistently up to 24 h. Therefore, additional mechanisms of injury involving JNK activation need to be considered. To address this issue, I treated mice with the JNK inhibitor, SP600125 1h before APAP (600 mg/kg). SP600125 reduced peroxynitrite formation; however, it did not have any significant effect on the level of nitrate and nitrite in plasma. Moreover, L-N-(1-iminoethyl)lysine (L-Nil), a specific iNOS inhibitor, attenuated neither plasma nitrate and nitrite levels nor hepatic injury after APAP injection. Taken together, SP600125 reduced peroxynitrite formation by decreasing superoxide formation. In summary, my investigation demonstrated that JNK is a critical factor for Bax translocation, which causes mitochondria outer membrane pore formation. In addition, JNK accelerates peroxynitrite generation via induction of superoxide formation.
In conclusion, I demonstrated the efficacy of three protective strategies against APAP-induced hepatotoxicity: Mechanism of protection A: Preventing NAPQI binding to proteins (e.g., induction of MT gene expression); Mechanism of protection B: Scavenging (GSH, NAC) or reducing (JNK inhibition) the formation of reactive oxygen species; and Mechanism of protection C: Supplying mitochondrial energy substrates (GSH, NAC).
# TABLE OF CONTENTS

ACKNOWLEDGMENTS---------------------------------------------------------------3

ABSTRACT---------------------------------------------------------------------5

TABLE OF CONTENTS-------------------------------------------------------------9

LIST OF ABBREVIATIONS---------------------------------------------------------10

CHAPTER 1: GENERAL INTRODUCTION----------------------------------------------13

CHAPTER 2: HYPOTHESIS AND AIMS----------------------------------------------47

CHAPTER 3: MATERIALS AND METHOD--------------------------------------------49

CHAPTER 4: NOVEL MECHANISMS OF PROTECTION AGAINST ACETAMINOPHEN HEPATOTOXICITY IN MICE BY GLUTATHIONE AND N-ACETYLCYSTEINE-------------------------------------------------60

CHAPTER 5: MECHANISM OF PROTECTION BY METALLOTHIONEIN AGAINST ACETAMINOPHEN HEPATOTOXICITY------------------------------------------------------------93

CHAPTER 6: ROLE OF C-JUN-N-TERMINAL KINASE IN ACETAMINOPHEN-INDUCED LIVER INJURY--------------------------------------------127

CHAPTER 7: CONCLUSION AND CLINICAL RELEVANCY-------------------------------169

CHAPTER 8: REFERENCES CITED------------------------------------------------175
ABBREVIATIONS

°C   Celsius
AIF  Apoptosis inducing factor
ALT  Alanine aminotransferase
AMAP 3’-hydroxyacetanilide
ANT  Adenine nucleotide translocator
Anti-Fas Agonistic anti-Fas antibody
APAP  Acetaminophen
ASC  Apoptosis-associated speck-like protein containing caspase recruitment domain
Bad  Bcl-2 associated death promoter
Bak  Bcl-2 antagonist/killer 1
Bax  Bcl-2 associated X protein
Bcl-2  B cell lymphoma 2
Bcl-XL  Bcl-2 like 1
BH3  Bcl-2 homology 3
Bid  BH3 interacting domain
Bik  Bcl-2 interacting killer
Bim  Bcl-2 interacting mediator of cell death
Bok  Bcl-2 related ovarian killer
CAD  Caspase activated DNase
CAMs  Cellular adhesion molecules
CARD  Caspase recruitment domains
CK  Creatine kinase
COX  Cyclooxygenase
CsA  Cyclosporin A
CyD  Cyclophilin D
DMSO  Dimethyl sulfoxide
DNase  Deoxyribonuclease
DTNB  Dithionitrobenzoic acid
ER  Endoplasmic reticulum
Endo G  Endonuclease G
GdCl₃  Gadolinium chloride
GPx  Glutathione peroxidase
GSH  Glutathione
h  Hour
HK  Hexokinase
HOCl  Hypochlorous acid
ICAM-1  Intercellular cell adhesion molecules
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFN-γ</td>
<td>Interferon-γ</td>
</tr>
<tr>
<td>IgG</td>
<td>Immunoglobulin G</td>
</tr>
<tr>
<td>IL-</td>
<td>Interleukins</td>
</tr>
<tr>
<td>IL-1 R</td>
<td>IL-1 receptor</td>
</tr>
<tr>
<td>IL-1RA</td>
<td>IL-1 receptor antagonist</td>
</tr>
<tr>
<td>IM</td>
<td>Inner mitochondrial membrane</td>
</tr>
<tr>
<td>JNK</td>
<td>c-Jun N-terminal protein kinase</td>
</tr>
<tr>
<td>kDa</td>
<td>Kilodaltons</td>
</tr>
<tr>
<td>KO mice</td>
<td>Knockout mice</td>
</tr>
<tr>
<td>L-Nil</td>
<td>L-N&lt;sup&gt;6&lt;/sup&gt;-(1-iminoethyl)-lysine</td>
</tr>
<tr>
<td>LPO</td>
<td>Lipid peroxidation</td>
</tr>
<tr>
<td>LPS</td>
<td>Lipopolysaccharide</td>
</tr>
<tr>
<td>M</td>
<td>Molar</td>
</tr>
<tr>
<td>Mcl-1</td>
<td>Myeloid cell leukemia-1</td>
</tr>
<tr>
<td>Min</td>
<td>Minute</td>
</tr>
<tr>
<td>mL</td>
<td>Milliliter</td>
</tr>
<tr>
<td>MOMP</td>
<td>Mitochondrial outer membrane permeabilization</td>
</tr>
<tr>
<td>MPO</td>
<td>Myeloperoxidase</td>
</tr>
<tr>
<td>MPT</td>
<td>Mitochondrial membrane permeability transition</td>
</tr>
<tr>
<td>NAC</td>
<td>N-acetylcysteine</td>
</tr>
<tr>
<td>Nalp3</td>
<td>NACHT, LRR, and pyrin domain-containing protein 3</td>
</tr>
<tr>
<td>NAPQI</td>
<td>N-acetyl-p-benzoquinone imine</td>
</tr>
<tr>
<td>NK</td>
<td>Natural killer</td>
</tr>
<tr>
<td>NKT</td>
<td>Natural killer with T-cell receptors</td>
</tr>
<tr>
<td>NO</td>
<td>Nitric oxide</td>
</tr>
<tr>
<td>OM</td>
<td>Outer mitochondrial membrane</td>
</tr>
<tr>
<td>p53</td>
<td>Protein 53</td>
</tr>
<tr>
<td>PBR</td>
<td>Peripheral-type benzodiazepine receptor</td>
</tr>
<tr>
<td>PC</td>
<td>Pyruvate carboxylase</td>
</tr>
<tr>
<td>PDH</td>
<td>Pyruvate dehydrogenase</td>
</tr>
<tr>
<td>Prx</td>
<td>Peroxiredoxin</td>
</tr>
<tr>
<td>Puma</td>
<td>p53-upregulated modulator of apoptosis</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive oxygen species</td>
</tr>
<tr>
<td>Smac</td>
<td>Second mitochondria-derived activator of caspases</td>
</tr>
<tr>
<td>SODs</td>
<td>Superoxide dismutases</td>
</tr>
<tr>
<td>tBid</td>
<td>Truncated Bid</td>
</tr>
<tr>
<td>TLR</td>
<td>Toll-like receptor</td>
</tr>
<tr>
<td>TNF R</td>
<td>Tumor necrosis factor receptor</td>
</tr>
<tr>
<td>TNF-Rp55</td>
<td>TNF receptor with a molecular weight of 55 kDa</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Tumor necrosis factor α</td>
</tr>
<tr>
<td>TOM</td>
<td>Translocase of the outer mitochondrial membrane</td>
</tr>
<tr>
<td>TUNEL</td>
<td>Terminal deoxynucleotidyl transferase-mediated dUTP nick-ending labeling</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>U</td>
<td>Unit</td>
</tr>
<tr>
<td>VCAM-1</td>
<td>Vascular cell adhesion molecule</td>
</tr>
<tr>
<td>VDAC</td>
<td>Voltage-dependent anion channel</td>
</tr>
<tr>
<td>WT</td>
<td>Wild type</td>
</tr>
<tr>
<td>ZVAD-FMK</td>
<td>Benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone</td>
</tr>
<tr>
<td>μg</td>
<td>Microgram</td>
</tr>
<tr>
<td>μl</td>
<td>Microliter</td>
</tr>
</tbody>
</table>
CHAPTER 1: GENERAL INTRODUCTION

1) APAP-induced cell death: apoptosis versus oncotic necrosis

It has been discussed whether APAP overdose induces apoptotic or necrotic cell death. Apoptosis and necrosis are defined by characteristic morphological changes of the cell (table 1). In apoptotic cell death, a cell undergoes shrinkage, shows chromatin condensation in the nucleus, and eventually breaks down into apoptotic bodies. In contrast, oncotic necrosis is characterized by cell swelling, chromatin flocculation, and absence of vesicle formation. It has been reported that apoptosis has a critical role in APAP-induced liver failure (Ferret et al., 2001; Zhang et al., 2000b). It was observed that after APAP administration, the pro-apoptotic Bcl-2 family member Bax translocated to mitochondria (Bajt et al., 2008), mitochondrial cytochrome c was released (Bajt et al., 2008), and DNA fragments could be detected on an agarose gel (Cover et al., 2005b), all of which occur in apoptotic cell signaling. However, based on morphological evidence, APAP appears to induce oncotic necrosis in the centrilobular area in vivo (Gujral et al., 2002). In addition, none of the above mentioned indicators are specific for apoptosis and have been shown to be positive in oncotic necrosis (Bajt et al., 2008).
<table>
<thead>
<tr>
<th>Apoptosis</th>
<th>Oncotic Necrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membrane blebbing, but no loss of integrity</td>
<td>Loss of membrane integrity</td>
</tr>
<tr>
<td>Aggregating of chromatin at the nuclear membrane</td>
<td>Flocculation of chromatin</td>
</tr>
<tr>
<td>Cell shrinkage</td>
<td>Swelling of the cell and lysis</td>
</tr>
<tr>
<td>Formation of membrane bound vesicles (apoptotic bodies)</td>
<td>No vesicle formation, complete lysis</td>
</tr>
<tr>
<td>No disintegration of organelles: organelles remain intact</td>
<td>Disintegration (swelling) of cell organelles</td>
</tr>
</tbody>
</table>

**Table 1-1**

**Morphological characteristics for apoptosis and oncotic necrosis**

2) **The mechanism of APAP-induced hepatotoxicity**

a) **APAP metabolism and protein binding**

APAP is eliminated mainly as nontoxic conjugates with glucuronic acid via glucuronyltransferase (Nelson, 1990, 1995) and excreted into bile through the canalicular multidrug resistance-associated protein 2 (Mrp2, Abcc2) or into blood through Mrp3 (Abcc3) (Xiong et al., 2000). APAP is also conjugated with sulfate through sulfotransferases and is eliminated into bile mainly via Mrp2, and to lesser degree via breast cancer resist protein (BCRP, ABCG2) (Zamek-Gliszczynski et al., 2005). A small part of the APAP dose is metabolized to a reactive metabolite NAPQI by CYP2E1, CYP1A2, and CYP3A4 in liver microsomes.
Figure 1.1
Scheme for APAP overdose metabolism. Modified from (James et al., 2003b).

It has been shown that NAPQI reacts very rapidly with GSH \( k_1 = 3.2 \times 10^4 \) \( \text{M}^{-1} \text{s}^{-1} \) at pH 7.0) (Coles et al., 1988). Therefore, after NAPQI formation following APAP overdose, the GSH concentration becomes very low in the centrilobular cells (Figure 1.1). Following depletion of GSH, remaining NAPQI reacts with cysteinyl sulfhydryl groups on proteins to produce the corresponding 3-(cystein-S-yl)acetaminophen adduct. No other sites of binding to protein have been identified in vivo (Roberts et al., 1987). It has
been demonstrated by mass spectrometry that approximately 40 proteins can react with APAP metabolites (Qiu et al., 1998). The covalent modification of cellular proteins was originally thought to be the cause of necrotic cell death, which is supported by the fact that prevention of covalent binding can reduce cell death (Jollow et al., 1973; Mitchell et al., 1973a; Mitchell et al., 1973b). However, it was reported that total binding to cellular proteins may be less relevant than selective modifications of specific critical targets. The regioisomer of APAP, 3'-hydroxyacetanilide (AMAP) can cause GSH depletion and a similar degree of covalent binding to cellular proteins as APAP; however, AMAP does not cause liver injury (Tirmenstein and Nelson, 1989).

Furthermore, APAP administration depleted mitochondrial GSH to a greater extent than AMAP. Moreover, APAP metabolites bound more extensively to mitochondrial proteins than AMAP (Tirmenstein and Nelson, 1989). This indicated that mitochondria are a target for covalent binding of NAPQI, which is a critical event in APAP-induced hepatotoxicity (Gupta et al., 1997; Pumford et al., 1990; Tirmenstein and Nelson, 1989).

b) Mitochondria respiration

Succinate dehydrogenase (associated with respiratory complex II) is very sensitive to NAPQI because it contains a number of cysteine-rich sulfur clusters. In addition, NAPQI inhibits NADH dehydrogenase (complex I) to a lesser extent. However, NAPQI does not have any effect on the activities of either ubiquinol-cytochrome c oxidoreductase (complex III) or cytochrome
oxidase (complex IV) in hepatocytes. (Burcham and Harman, 1991). Moreover, exposure of both rat and mouse liver mitochondria to NAPQI has been shown to result in the irreversible inhibition of mitochondrial respiration (Esterline et al., 1989; Ramsay et al., 1989). Taken together, these data suggest that NAPQI binds to mitochondrial respiration chain complexes and disrupts energy homeostasis, which contributes to APAP-induced hepatotoxicity.

c) Oxidative stress

Inhibition of mitochondrial respiration by NAPQI causes accumulation of reactive oxygen species (ROS). ROS are generated by one electron reduction of molecular oxygen (\( \text{O}_2 \)). During the spontaneous dismutation of superoxide (\( \text{O}^-_2 \)), singlet oxygen (\( \text{O}^1\text{O}_2 \)) plus hydrogen peroxide are formed.

Superoxide reacts with Cu\(^{2+}/\text{Zn}^{2+}\) - or Mn\(^{3+}\) -superoxide dismutase (SOD) in the cytosol and nucleus or in the mitochondria, respectively (Slot et al., 1986), which produced molecular oxygen (\( \text{O}_2 \)) and hydrogen peroxide (\( \text{H}_2\text{O}_2 \)). \( \text{H}_2\text{O}_2 \) is more stable than \( \text{O}^-_2 \) and quickly diffuses across membranes. In the presence of ferrous iron (Fe\(^{2+}\)), \( \text{H}_2\text{O}_2 \) can be reduced to the highly reactive OH\(^-\) radical (Fenton reaction), which initiates lipid peroxidation (LPO).

Uchiyama et al demonstrated that ROS induce the release of chelatable iron from lysosomes. The iron is taken up by mitochondria via the calcium uniporter (Uchiyama et al., 2008). Wendel and coworkers showed that APAP metabolism triggers massive LPO, which corresponded with hepatotoxicity in
vitamin E-deficient mice (Wendel and Feuerstein, 1981; Wendel et al., 1979). However, mice fed a normal diet showed only minor LPO (Knight et al., 2003). Moreover, enhancing levels of α-tocopherol acetate in the liver by either repeated injections of α-tocopherol or by feeding high d-α-tocopheryl acetate diet did not have any effect on APAP-induced liver injury (Knight et al., 2003). Taken together, LPO may not be involved in APAP-induced liver toxicity.

However, if nitric oxide (NO) is present, O$_2^-$ reacts with NO and forms peroxynitrite (ONOO$^-$), which causes nitration of proteins (Belizario et al., 2007; James et al., 2003a). It has been reported that peroxynitrite formation, which can be detected by immunohistochemical staining against anti-nitrotyrosine protein adducts, occurs in the mitochondria after APAP injection (Cover et al., 2005b). The rate of peroxynitrite formation depends on the concentrations of both NO and superoxide (Koppenol, 1998; Squadrito and Pryor, 1998). The source of NO formation remains unclear. Hepatocytes, stellate cells and Kupffer cells express inducible nitric oxide synthase (iNOS) and endothelial cells constitutively express eNOS (Muriel, 2000). It was reported that APAP-induced liver toxicity was significantly lower in eNOS knockout (KO) and iNOS KO mice compared to wild type (WT) animals. In addition, plasma nitrate and nitrite levels were higher in WT animals than in both KO animals (Salhanick et al., 2006). Although Michael et al. showed that serum ALT levels were lower in iNOS knockout mice, which is consistent with the previous data, there was no significant difference in tissue injury as
assessed by histology (Michael et al., 2001). In terms of NOS inhibitors, a selective iNOS inhibitor, \( L-N^6-(1\text{-iminoethyl})\text{-lysine} \) (L-Nil) did protect against APAP-induced liver injury; however, a nonselective NOS inhibitor, \( N^\beta\)-nitro-L-arginine methyl ester (L-NAME) did not (Ito et al., 2004). Others did not find protection with various iNOS inhibitors (Hinson et al., 2002). Therefore the source of NO during APAP-induced liver injury needs further investigation.

Mitochondrial DNA (mtDNA) may be a target of ROS due to close proximity to the electron transport chain and a lack of protective histones (Ott et al., 2007a). mtDNA is essential for electron transport and ATP generation by oxidative phosphorylation. Therefore, mtDNA damage can cause respiratory dysfunction (Anderson et al., 1981). It was shown that mitochondrial oxidant stress can cause depletion of mitochondrial DNA (mtDNA) in several in vivo models, such as alcohol binge drinking (Mansouri et al., 1999) and tacrine hepatotoxicity (Mansouri et al., 2003). In the APAP model, there is a significant reduction of mtDNA between 3 and 12h after APAP administration. However, scavenging of peroxynitrite with GSH partially prevented the loss of mDNA, suggesting that peroxynitrite was, at least in part, responsible for the mtDNA loss (Cover et al., 2005b).

d) Antioxidant defense

There are many antioxidant defense systems to handle both the continuous formation of reactive oxygen and reactive nitrogen species in physiological
and pathophysiological conditions. For example, superoxide is removed by superoxide dismutases (SODs). Cu\(^{2+}\)/Zn\(^{2+}\)-SOD (SOD1) is mainly located in the cytosol and nuclear matrix, and Mn\(^{3+}\)-SOD (SOD2) is present in the mitochondria (Slot et al., 1986). The high intracellular SOD levels (approx. 10 \(\mu\)M) keep the steady-state levels of superoxide in the range of 1 to 10 pM (Cadenas and Davies, 2000; Koppenol, 1998). What is the advantage of high SOD expression when superoxide alone is not very toxic? The main reason for the importance of SOD might be to limit peroxynitrite generation (Koppenol, 1998; Squadrito and Pryor, 1998). The rate of depletion for superoxide is 20000/sec with SOD (approx. 10 \(\mu\)M), but only 200/sec with NO (approx. 10 nM under physiological conditions) (Squadrito and Pryor, 1998). Therefore, SOD prevents peroxynitrite formation under physiological conditions.

Hydrogen peroxide formed by SOD is detoxified by catalase and glutathione peroxidase (GPx). Most of the cellular catalase is located in peroxisomes, and the main function of the enzyme is to metabolize hydrogen peroxide generated by oxidases in the peroxisomes. However, it was reported that catalase may be constitutively expressed in rodent liver mitochondria (Salvi et al., 2007). Further, the 30% reduction of catalase activity has been demonstrated after APAP overdose (Lores Arnaiz et al., 1995), and this might be involved in APAP-induced hepatotoxicity. These results suggested that catalase could be a key antioxidant enzyme during APAP hepatotoxicity. However, whether this small reduction in catalase activity has any
pathophysiological relevance remains unclear because massive catalase induction did not reduce APAP hepatotoxicity (Chen et al., 2002). Another antioxidant enzyme, glutathione peroxidase (GPx-1) is located in the cytosol (75%) and mitochondria (25%), and it was reported that cellular GPx could also reduce peroxynitrite in vitro (Sies et al., 1997). In spite of this, APAP-induced peroxynitrite-dependent injury was not increased in GPx-1 knockout mice (Knight et al., 2002). It is known that cellular GPx-1 can reduce peroxides, including hydrogen peroxide and organic peroxides (Brigelius-Flohe, 1999), and this requires GSH as a cofactor, but has a low specificity for peroxide. During the reduction of the peroxide, GSH is oxidized to glutathione disulfide (GSSG). Normally GSSG is reduced back to GSH by glutathione reductase and NADPH (>95%) or excreted into bile and plasma from hepatocytes (<5%) (Lauterburg et al., 1984). However, extreme oxidative stress can overwhelm these processes leading to accumulation of GSSG, because the glutathione reductase is the rate-limiting step of this cycle. In addition, GSSG can not be exported from mitochondria although mitochondria take up and release GSH (Olafsdottir and Reed, 1988).

GSH is the most important water-soluble antioxidant and it is used as a cofactor for GPxs and GSTs. Other low-molecular-weight antioxidants include ascorbate (vitamin C), \( \alpha \)-tocopherol (vitamin E). GSH is not only present in the cytosol, but also in mitochondria, which contain 15% of total cellular GSH (Fernandez-Checa and Kaplowitz, 2005). GSH is a tripeptide of
glutamic acid, glycine and cysteine, which is formed in the cytosol by two ATP-dependent enzymes, $\gamma$-glutamylcysteine synthetase and GSH synthetase (Figure 1.2). Because of its $\gamma$-glutamyl bond, GSH can be degraded only by $\gamma$-glutamyltranspeptidase, which is located on the surface of epithelial cells in the kidney, lung, and intestine and in the biliary tract. It was previously shown that the half-life of intravenously injected GSH in plasma is less than 5 min in starved animals (Wendel and Jaeschke, 1982). Therefore, injected GSH is degraded in the kidney and the amino acids are re-absorbed and then taken up by hepatocytes for GSH synthesis.

![Figure 1.2](image)

**Figure 1.2**

GSH synthesis.
e) Innate immunity

The innate immune response is the first line of defense against microbes and toxins (Janeway and Medzhitov, 2002). Kupffer cells, the resident macrophages in the liver, are highly phagocytic and are able to remove microorganisms. In addition, they can produce inflammatory mediators leading to invasion of inflammatory cells, such as neutrophils, monocytes, T and B lymphocytes as well as natural killer (NK) cells in the liver. Neutrophils accumulate within the hepatic microvasculature before they extravasate into liver parenchyma (Ramaiah and Jaeschke, 2007). Many inflammatory mediators, such as tumor necrosis factor α (TNF-α), interleukin-1 (IL-1), CXC chemokine and platelet activating factor (PAF) can cause neutrophil accumulation within the hepatic microvasculature (Jaeschke and Hasegawa, 2006). Chemokines represent a large family of chemotactic peptides that can be produced by hepatocytes, sinusoidal endothelium, cholangiocytes, Kupffer cells and stellate cells (Ramaiah and Jaeschke, 2007). The exposure to inflammatory mediators triggers mobilization of secretory granules and increased adhesion molecule expression on neutrophils, resulting in priming and activation of cells. In general, neutrophil activation/accumulation within sinusoids and postsinusoidal venules typically does not cause liver damage (Ramaiah and Jaeschke, 2007).

Extravasation into the parenchyma is required to fully activate neutrophils, which can generate reactive oxygen species and cause tissue
damage (Chosay et al., 1997). Normally, the adhesion molecules β2 integrin/intracellular cell adhesion molecules (ICAM)-1 and β1 integrin/vascular cell adhesion molecule (VCAM)-1 interactions are involved in the migration of neutrophils into parenchyma, which is a prerequisite of neutrophil-mediated injury (Chosay et al., 1997; Essani et al., 1997; Essani et al., 1995). However, during extensive endothelial damage resulting from ischemia-reperfusion, neutrophils can extravasate directly into the parenchyma without cellular adhesion molecules (CAMs) (Farhood et al., 1995). Independent of the condition of the endothelial cell barrier, signaling from parenchymal cells or extravasated neutrophils is required for neutrophil migration. It was reported that lipid peroxidation products including lipid aldehydes are potent chemotactic factors for neutrophils (Jaeschke, 2000). In addition, CXC chemokines are chemotactic factors (Okaya and Lentsch, 2003), which have been shown to contribute to the promotion of neutrophilic hepatitis during ischemia-reperfusion injury (Colletti et al., 1996; Lentsch et al., 1998). However, the massive amounts of CXC chemokines generated in parenchymal cells during endotoxemia do not cause neutrophil extravasation when endotoxin is administered alone (Dorman et al., 2005). Moreover, CXC chemokines, MIP-2 and KC, in circulation are much less effective in recruiting neutrophils into the hepatic vasculature and activation of neutrophils in vivo, compared to cytokines or complement (Bajt et al., 2001). Therefore, further
studies are necessary to investigate the mechanism of neutrophils activation and extravasation.

Once extravasated, the neutrophils will adhere to the target, i.e. parenchymal cells. Upon activation, neutrophils generate superoxide via NADPH oxidase which is a multicomponent enzyme system that assembles at the cell membrane (El-Benna et al., 2005). Superoxide dismutases converts superoxide to hydrogen peroxide, which can be used by neutrophil-derived myeloperoxidase (MPO) to generate a potent oxidant, hypochlorous acid (HOCl) (El-Benna et al., 2005). Hypochlorous acid also can react with amino groups forming toxic chloramines (Bilzer and Lauterburg, 1991). In addition to ROS, neutrophil-derived serine proteases are known to contribute to hepatocyte damage (Jaeschke and Smith, 1997a, b) (Figure 1.3).
Figure 1.3

Proposed mechanisms for neutrophil-mediated liver pathology. Modified from (Jaeschke, 2006)
The involvement of innate immunity in APAP-induced hepatotoxicity is controversial. It was reported that APAP treatment induced Kupffer cell activation (Laskin and Pilaro, 1986) and migration of neutrophils into the liver (Lawson et al., 2000). Kupffer cells have been implicated in the mechanism of hepatocellular injury and peroxynitrite formation after APAP overdose (Laskin et al., 1995; Michael et al., 1999). Mice treated with APAP plus gadolinium chloride (GdCl₃), a macrophage inhibitor, decreased hepatotoxicity as evidenced by lower ALT levels (Michael et al., 1999). In contrast, mice treated with APAP plus liposome-entrapped clodronate, an effective Kupffer cell-depleting agent, increases APAP-induced hepatotoxicity (Ju et al., 2002). Ju et al. showed that the difference between gadolinium chloride treated mice and liposome-entrapped clodronate is IL-10 level in the liver. IL-10, which is produced by macrophages is completely inhibited by the Kupffer cell-depleting agent, liposome-entrapped clodronate treated group (Ju et al., 2002). These results are supported by the fact that IL-10 KO mice are more susceptible after APAP administration via induction of iNOS mRNA expression. Furthermore, serum nitrite-nitrate levels were significantly elevated in IL-10 KO mice after APAP administration (Bourdi et al., 2002). Moreover, it was reported that peroxynitrite formation was increased in sinusoidal endothelial cells during the early phase after APAP administration (Knight et al., 2001). However, GdCl₃ treatment had no effect on peroxynitrite
formation in vascular endothelial cells or parenchymal cells (Liu et al., 1995). This suggests an intracellular oxidant stress and peroxynitrite formation in sinusoidal endothelial cells rather than a Kupffer cell-derived oxidant stress. Furthermore, the most active Kupffer cells are located in the periportal area (Bautista et al., 1990; Jaeschke et al., 1991) and activation of these cells in ischemia-reperfusion model results in a periportal to midzonal injury (Jaeschke and Farhood, 1991). In contrast, APAP causes strict centrilobular necrosis. Therefore, overall these results indicate that Kupffer cells are not a relevant source of vascular oxidant stress during APAP hepatotoxicity.

It is controversial whether polymorphonuclear leukocytes (neutrophils) are relevant for APAP-induced liver injury. The presence of neutrophils in the areas of necrosis after APAP overdose injection was first demonstrated by Mitchell et al (Mitchell et al., 1973a), but the pathophysiological relevance of this observation was unclear. Cover et al showed that the location of most neutrophils was outside the area of necrosis, which was in contrast to models where neutrophils caused liver cell injury (Cover et al., 2006). Inflammatory cytokines and CXC chemokines were also increased after APAP administration (Horbach et al., 1997; Lawson et al., 2000; Takada et al., 1995); however, there was no upregulation of Mac-1 (CD11b/CD18) on circulating neutrophils. Moreover, an anti-CD18 antibody had no protective effect against APAP overdose (Lawson et al., 2000). In addition, mice deficient in ICAM-1, a counter receptor for Mac-1, were not
protected against APAP-induced hepatotoxicity (Cover et al., 2006). Taken together, neutrophil migration into the parenchyma might not be relevant to APAP-induced hepatotoxicity. In terms of oxidative stress caused by neutrophils, despite the substantial number of neutrophils transmigrated into hepatocytes, there was no evidence for the generation of relevant amounts of HOCl-modified proteins, which is a specific marker for neutrophil-derived oxidant stress (Cover et al., 2006). Furthermore, animals deficient in gp91 phox, an essential protein of activated NADPH oxidase complex in phagocytes, did not show any protective effect after APAP administration (James et al., 2003b). In support of this finding, a chemical inhibitor of NADPH oxidase, DPI, did not decrease APAP-induced hepatotoxicity (Cover et al., 2006). Together, these data lead to the conclusion that neutrophils do not actively contribute to the injury.

Natural killer (NK) and natural killer T (NKT) cells, which play a role in defense against viral infection and tumor transformation, might be involved in APAP-induced liver toxicity. The liver contains a resident lymphocyte population, composed of 5-10% NK cells and 30-40% NKT cells in mice. (Gao et al., 2008; Gao et al., 2009). Liu et al. showed that depletion of NK, NKT cells by anti-NK1.1 significantly reduced APAP-induced hepatotoxicity by 1) reduction of interferon-γ (IFN-γ) secretion, which modulates inflammatory chemokine formation, 2) reduction of neutrophil accumulation, and 3) reduction of Fas ligand expression on innate immune cells (Liu et al., 2004).
Moreover, it was demonstrated that APAP-induced liver injury was significantly attenuated in IFN-γ-KO mice (Ishida et al., 2002). In addition, Fas deficient lpr mice and FasL-deficient gld mice showed significantly decreased APAP-induced hepatotoxicity (Liu et al., 2004). However, Masson et al. demonstrated that dimethyl sulfoxide (DMSO) activated hepatic NK and NKT cells in vivo, which was shown by induction of intracellular levels of IFN-γ and granzyme B. Importantly, depletion of NK, NKT cells protected against APAP-induced liver injury only with DMSO as vehicle. In the absence of DMSO, NK, NKT cells did not induce IFN-γ mRNA expression. In addition, there was no significant difference in liver injury between control and anti-NK1.1 pretreated groups after various doses of APAP in mice (Masson et al., 2008). Therefore, DMSO should be used cautiously in drug hepatotoxicity experiments. NK and NKT cells may only be involved in APAP hepatotoxicity if these cells are activated independently. Although it is known that APAP induces inflammatory gene expression in mice (Cover et al., 2006), the relevance of this for liver injury has not been determined.

The production of tumor necrosis factor-α (TNF-α) is one of the earliest events in the hepatic inflammatory response, and TNF-α is mainly released by activated liver macrophages (Decker, 1990). Ishida et al. reported that liver injury in mice deficient in the 55 KDa TNF receptor (TNF-Rp55) was attenuated after APAP challenge. In addition, APAP-induced mortality was reduced in TNF-Rp55 KO mice (Ishida et al., 2004). Moreover, post-treatment
of anti-TNF-α Ab at 2 hours and 8 hours after APAP administration reduced hepatotoxicity significantly, which was shown by serum ALT levels (Ishida et al., 2004). However, a reduction in TNF-α by pre-treatment with anti-TNF-α antibodies did not decrease APAP-induced liver injury (Simpson et al., 2000; Yee et al., 2007). In addition, TNF-α and lymphotixin-α double KO mice did not show any protection against APAP overdose (Boess et al., 1998). The reason for using these double knockout mice is that these two closely related cytokines may cross-compete for binding at the TNF receptors on target cells (Vandenabeele et al., 1995). In contrast, it was reported that TNF-Rp55 KO mice exaggerate APAP-induced hepatotoxicity (Gardner et al., 2003). Therefore, further studies need to be conducted to elucidate how TNF signaling is involved in APAP-induced liver injury.

It has been recently discussed whether another proinflammatory cytokine, IL-1, is involved in APAP-induced hepatotoxicity. There are two distinct types of IL-1, IL-1α and IL-1β, both of which signal through IL-1 receptor (IL-1 R). IL-1β is a very potent proinflammatory cytokine, which requires processing by activated caspase-1 (Mariathasan et al., 2004; Martinon et al., 2002; Ogura et al., 2006). It is known that the combination of two distinct signaling pathways triggers caspase 1 activation. One is the activation of a cytosolic protein complex called the inflammasome. Three types of inflammasomes are reported based on biochemical analysis of three Apaf-1-like proteins, NALP1, NALP2, NALP3 (Agostini et al., 2004). The
NALP3 inflammasome is composed of NALP3, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) which is the adaptor protein, and caspase 1 (Trendelenburg, 2008). The other pathway involves activation of immune cells, such as macrophages, via Toll-like receptor (TLR) agonists, which induces the synthesis of pro-IL-1-β via NF-κB and certain inducible components of the inflammasome (Mariathasan and Monack, 2007). In the APAP model, it was reported that TLR9 and the NALP3 inflammasome play critical roles in the induction of hepatotoxicity in mice (Imaeda et al., 2009). In addition, C3H/HeJ mice, which have a mutated TLR4, showed significant reduction of APAP-induced injury compared to controls without changing hepatic GSH level (Yohe et al., 2006). Furthermore, IL-1 receptor KO mice showed a dramatic reduction of APAP-induced liver injury and MPO activity (Chen et al., 2007). In addition, pretreatment with a combination of antibodies to IL-1-α, IL-1-β, and IL-1 R also decreased APAP-induced hepatotoxicity (Chen et al., 2007). In spite of that, the genetic disruption of IL-1-receptor antagonist (IL-1RA), which binds the IL-1 R at the same sites with similar affinity as IL-1 but fails to induce effective signaling (Dinarello, 1996; Dripps et al., 1991), reduced hepatotoxicity in the APAP model (Ishibe et al., 2009). It was reported that the reason for this protection was inhibition of APAP metabolism in IL-RA KO mice. These data are supported by the observation that IL-1 signaling suppresses CYP gene
transcription via activation of NF-κB (Cao et al., 1999; Riddick et al., 2004; Zhou et al., 2006).

In terms of other cytokines, it was demonstrated that APAP-induced hepatotoxicity is increased in IL-13 deficient mice, as well as by IL-13 neutralizing antibody pretreatment (Yee et al., 2007). The mechanism has not been investigated yet, but IL-13 may have a regulatory role in modulating the infiltration of neutrophils into hepatocytes following APAP.

Previously, it was shown that IL-10 and IL-4 synergistically inhibit macrophage cytotoxic activity (Oswald et al., 1992). Recently, it was reported that IL-10/4 double knockout mice are highly sensitive to APAP-induced hepatotoxicity without disturbance of its metabolism (Bourdi et al., 2007). In addition, pretreatment with an IL-6 neutralizing antibody 1 hour prior to APAP reduced liver injury in IL-10/4 KO mice (Bourdi et al., 2007), suggesting that in IL-10/4 KO mice, IL-6 promoted hepatotoxicity.

Taken together, whether innate immunity is relevant for APAP-induced hepatotoxicity is still highly controversial, and it is necessary to do more and better mechanistic studies to resolve these issues.

**f) Mitochondrial outer membrane permeabilization (MOMP) and Mitochondrial permeability transition (MPT)**

The mitochondrial permeability transition (MPT) is characterized by mitochondrial swelling, and inner membrane permeabilization to solutes of molecular mass up to 1500 Da (Waldmeier et al., 2003).
MPT pore consists of cyclophilin D (CyD) in the matrix, the adenine nucleotide translocase (ANT) in the inner mitochondrial membrane (IM), the voltage-dependent anion channel (VDAC) in the outer mitochondrial membrane (OM) and a number of accessory proteins (Orrenius et al., 2007). Direct interactions have been shown for ANT and CyD, as well as between ANT and VDAC (Crompton, 1999; Woodfield et al., 1998).

CyD in the matrix is thought to be involved in the regulation of MPT pore formation because it can interact with the immunosuppressant, cyclosporin A (CsA), which prevents MPT pore opening. Moreover, CyD knockout mice showed resistance to ischemia/reperfusion induced cardiac injury (Lim et al., 2007) (Figure. 1.4).

In healthy cells, the inner mitochondrial membrane (IM) is nearly impermeable to all ions, including protons. This allows complexes I-IV of the respiratory chain to build up, across the IM, the proton gradient that is required for ATP synthesis (Mitchell and Moyle, 1965a, b). Therefore, the transport of all metabolites that cross the IM is tightly regulated by highly selective channels and transport proteins. The ANT has been proposed to be a main component of the IM. The function of ANT is exchanging of ATP and ADP across the IM (Zamzami and Kroemer, 2001). The ANT-mediated exchange (antiport) of ATP and ADP across the inner mitochondrial membrane is a function that is essential for generation of ATP through oxidative phosphorylation (Klingenberg, 1980). It is reported that mitochondria
isolated from ANT1/ANT2 double KO hepatocytes are relatively resistant against Ca\(^{2+}\) -induced swelling, which indicates that ANT is involved in MPT regulation (Kokoszka et al., 2004). Interestingly, the formation of ANT pores is stimulated by Bax (Brenner et al., 2000; Marzo et al., 1998; Zamzami et al., 2000) as well as reactive oxygen species (Vieira et al., 2001).

The permeability of the OM is also regulated. It was shown that the OM is normally permeable to metabolites but not to proteins, which means that OM permeabilization results in the release of intermembrane proteins into the cytosol (Kroemer et al., 2007). The VDAC is the most abundant protein of the OM and it is known as a nonspecific pore, allowing diffusion of solutes up to 5 kDa (Gottlieb, 2000; Zamzami and Kroemer, 2001). It was demonstrated that overexpression of VDAC1 induces apoptosis in a variety of cells (Zaid et al., 2005).

A number of accessory proteins, such as hexokinase (HK), creatine kinase (CK), and peripheral-type benzodiazepine receptor (PBR) have been identified (Figure 1.4) (Kroemer et al., 2007). HK interacts with VDAC from the cytosol. The interaction between HK and VDAC might cause a conformational change which may prevent mitochondrial breakdown during cell stress and injury (Mathupala et al., 2006). However, this interaction can be disrupted by glycogen synthase kinase-3 beta (GSK-3β)-dependent phosphorylation of VDAC and can be promoted by Akt, which inhibits GSK-3β (Pastorino et al., 2005). Creatine kinase (CK) interacts with MPT pore complex from the IM
(Kroemer et al., 2007) and peripheral-type benzodiazepine receptor (PBR) is interacting with MPT pore complex from the OM (Kroemer et al., 2007). The exact functions of these proteins have not been identified yet (Zamzami and Kroemer, 2001).

Figure 1.4
Mitochondrial permeability transition pore formation. Modified from (Orrenius et al., 2007) Voltage-dependent anion channel (VDAC), Cyclophilin D (CyD), Adenine nucleotide translocase (ANT), Inner mitochondrial membrane (IM), Outer mitochondrial membrane (OM), Cyclosporin A (CsA), Hexokinase (HK), Creatine kinase (CK), Peripheral-type benzodiazepine receptor (PBR)

MPT pore formation is regulated in many ways. 1) MPT pore is closed at neutral or acidic pH. Alkalination is permissive for pore opening with a maximum effect at a matrix pH of ~7.3 (Zamzami and Kroemer, 2001). 2) It was reported that mitochondrial ROS accumulation causes MPT (Kowaltowski et al., 2001). Thiol groups of inner membrane proteins are
oxidized. This causes conformational changes, which lead to formation of a large non-selective pore (Kowaltowski et al., 2001). In particular, the oxidation of a critical residue (Cys56) of the ADP/ATP transporter leads to MPT pore opening in isolated mitochondria (Costantini et al., 2000). 3) An increase in matrix Ca$^{2+}$ enhances the probability of pore opening, while matrix Mg$^{2+}$ or Mn$^{2+}$ decrease it (Zamzami and Kroemer, 2001). In terms of calcium, high concentrations stimulate MPT via a decreased transmembrane electrical potential (Hunter and Haworth, 1979; Jurkowitz et al., 1983; Vercesi, 1987; Zago et al., 2000). In the APAP model, it was demonstrated that 1 h pretreatment with calcium channel blocking agents, e.g. diltiazem, verapamil, and gallopinamil, protected primary cultures of rat hepatocytes. In addition, it has been shown that verapamil prevents APAP-induced hepatotoxicity in vivo (Ray et al., 1993). Moreover, calcium can activate calpains, which are intracellular cysteine proteases that can cleave Bid and induce MPT and cell death. It has been shown that the specific calpain inhibitor, calpeptin, reduced AIF release in isolated mouse liver mitochondria (Polster et al., 2005). In addition, when N-CBZ-VAL-PHE methyl ester (CBZ), which is a calpain inhibitor, was administered 1 hour before APAP, liver injury was significantly reduced (Limaye et al., 2003). Furthermore, overexpression of calpastatin, which is an endogenous inhibitor of calpain, attenuated APAP-induced hepatotoxicity (Limaye et al., 2006).
4) Members of the Bcl-2 family have either anti-apoptotic or pro-apoptotic function (Ranger et al., 2001). The members are classified by sequence homology in four $\alpha$-helical segments, which are called BH1-BH4 (Gross et al., 1999). The highly conserved anti-apoptotic family members (Bcl-2, Bcl-xL, Mcl-1 and A1) contain all 4 BH domains. The pro-apoptotic members can be divided into 2 groups, multi-domain pro-apoptotic members (Bax, Bak, and Bok) and BH3 only members (Bid, Bad, Bim, Bik, Noxa and Puma) (Ranger et al., 2001) (Figure 1.5). It has been demonstrated that overexpression of the anti-apoptotic protein Bcl-2 increases the transmembrane electrical potential, which prevents MPT (Kowaltowski et al., 2000). Also, it has been reported that Bcl-2 and Bax can interact directly or indirectly with VDAC in the OM (Shimizu et al., 1999), whereas Bcl-2, Bcl-xL, Bax, and Bak interact directly with ANT (Marzo et al., 1998). Therefore, it is likely that the Bcl-2 family can regulate MPT to some extent.
<table>
<thead>
<tr>
<th>Pro-apoptotic</th>
<th>Multi-domain</th>
<th>BH3</th>
<th>BH1</th>
<th>BH2</th>
<th>Bax</th>
<th>Bak</th>
<th>Bok</th>
</tr>
</thead>
<tbody>
<tr>
<td>BH3 only domain</td>
<td>BH3</td>
<td></td>
<td></td>
<td></td>
<td>Bid, Bad, Bim, Bik, Noxa, Puma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-apoptotic</td>
<td>Multi-domain</td>
<td>BH4</td>
<td>BH3</td>
<td>BH1</td>
<td>BH2</td>
<td>Bcl-2, Bcl-xL, Mcl-1, A1</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1.5

Bcl-2 family of proteins. Modified from (Ronger et al. 2001)
Mitochondrial outer membrane permeabilization (MOMP) is also regulated by Bcl-2 family members (Orrenius et al., 2007) (Figure 1.6). Permeabilization of the OM is caused by the oligomeric form of Bax (Antonsson et al., 2000), which follows binding to the truncated form of the BH3-domain-only pro-apoptotic protein, Bid (Eskes et al., 2000). Anti-apoptotic proteins, such as Bcl-2 and Bcl-xL, interact with the pro-apoptotic proteins Bax or Bak, which prevents their oligomerization. It has been suggested that the ratio of Bcl-2 to Bax determines the amount of Bcl-2/Bax heterodimers versus Bax/Bax homodimers, which is important in determining the susceptibility to apoptosis (Yang and Korsmeyer, 1996).

Figure 1.6
Mitochondrial outer membrane permeabilization (MOMP) formation. Modified from (Orrenius et al. 2007).
Li, et al. showed that ROS can stimulate phosphorylation and ubiquitination of Bcl-2 family proteins, thereby controlling their expression (Li et al., 2004a). In addition, it was shown that activated c-Jun N-terminal protein kinase (JNK) can phosphorylate the anti-apoptotic proteins Bcl-2 and Bcl-xL resulting in inactivation. At the same time, JNK can phosphorylate Bax, which causes activation of Bax after APAP overdose (Latchoumycandane et al., 2007).

How does Bax recognize the proper membrane in which to insert itself? Several possible Bax receptors have been suggested. The first candidate for a mitochondrial Bax receptor was VDAC, which is also known as mitochondrial porin. Tsujimoto and colleagues showed that Bax enhances VDAC activity which regulates the mitochondrial membrane potential and the release of cytochrome c during apoptosis (Shimizu et al., 1999). However, absence of VDAC isoforms 1, 2 and 3 did not affect apoptosis signaling in fibroblasts isolated from VDAC 1-3 knockout mice (Baines et al., 2007). Other potential Bax receptors include various components of the translocase of the outer mitochondrial membrane (TOM complex). Tom 22 was found to interact with the N-terminal of Bax (Bellot et al., 2007). In addition, it was reported that antibodies against Tom 22 inhibit the association of truncated Bid (tBid) /Bax with rat liver mitochondria (Bellot et al., 2007; Cartron et al., 2008). In contrast, proteolytic removal of Tom22 did not prevent against tBid/Bax-induced cytochrome c release in yeast (Ott et al., 2007b). Another target of Bax is
cardiolipin, which binds to cytochrome c in the IM and limits cytochrome c release during apoptosis (Ott et al., 2002). However, there is very little cardiolipin in the OM, representing around 0.3% of the total phospholipids in mitochondria from rat liver (de Kroon et al., 1997). Therefore, it is not known yet how Bax receptors are involved in MOMP formation.

**g) Intermembrane proteins and DNA damage**

After outer mitochondrial membrane permeabilization, intermembrane proteins, such as EndoG, AIF, cytochrome c, Smac/Diablo, HtrA2/Omi, AIF, and EndoG are released (Er et al., 2006). Cytochrome c, Smac/Diablo and HtrA2/Omi are released into the cytosol, which is necessary for the activation of caspases in the mitochondrial apoptotic pathway (Wang, 2001). Despite inducing cytochrome c release, APAP does not induce caspase-3 activation (Knight and Jaeschke, 2002; Lawson et al., 1999). Furthermore, it was shown that post-treatment with a pancaspase inhibitor, ZVAD-FMK (benzyloxy carbonyl-Val-Ala-Asp-fluoromethylketone) did not protect against APAP hepatotoxicity (Lawson et al., 1999). However, a subsequent report showed a protective effect with pre-treatment of ZVAD-FMK (El-Hassan et al., 2003). Most likely, the solvent dimethyl sulfoxide (DMSO) used to dissolve the inhibitor attenuated the APAP metabolism (Jaeschke et al., 2006). Thus, DNA fragmentation observed after APAP overdose is independent of the caspase-activated DNase (CAD).
EndoG and AIF are involved in DNA damage after translocation from mitochondria to the nucleus in APAP overdose (Bajt et al., 2006). AIF is thought to trigger chromatin condensation and can induce large scale DNA fragmentation (50-300 kb) (Susin et al., 1999). EndoG and Mn$^{2+}$ dependent endonuclease can produce oligonucleosomal DNA fragments (Li et al., 2001). Subsequent studies also demonstrated that EndoG catalyzes both high-molecular-weight DNA cleavage and oligonucleosomal DNA breakdown in a sequential fashion (Widlak et al., 2001). It was observed that AIF KO mice have reduced APAP-induced DNA fragmentation and liver injury (Jaeschke, 2007), indicating that AIF could be a key target for protection against APAP hepatotoxicity.

Another nuclease is deoxyribonuclease 1 (DNase 1). DNase 1 is a Ca$^{2+}$/Mg$^{2+}$-dependent endonuclease, which cleaves double-stranded DNA into 3'-OH/5'-phospho tri-and/or tetra-oligonucleotides (Napirei et al., 2005). DNase1 gene expression has been demonstrated in many different organs, including the murine liver (Napirei et al., 2004a). Extracellular DNase1 diffuses into necrotic cells and, together with the plasminogen system, induces necrotic chromatin breakdown in vitro (Napirei et al., 2004b). A recent study showed that DNase 1 KO mice suffered less liver injury after APAP overdose (Napirei et al., 2006). It was concluded that DNase 1 caused some of the DNA damage and aggravated energy depletion via stimulation of DNA repair mechanisms, such as poly-adenosine diphosphate-ribose polymerase.
(PARP) activation during APAP-induced hepatotoxicity (Jacob et al., 2007; Napirei et al., 2006). In addition, it was reported that excessive PARP-1 activation leads to depletion of nicotinamide adenine dinucleotide (NAD\(^+\)) and ATP content that causes oncotic necrosis (Charron and Bonner-Weir, 1999; Ha and Snyder, 1999; Szabo and Dawson, 1998; Virag and Szabo, 2002). These data are supported by the fact that nicotinamide supplementation also decreases APAP-induced hepatotoxicity (Ray et al., 2001). However, neither PARP-1 KO mice (Cover et al., 2005a) nor cultured hepatocytes treated with a PARP inhibitor (Shen et al., 1992) were protected against APAP-induced liver injury. Therefore PARP activation does not appear to be critical for APAP hepatotoxicity. However, DNase 1 may contribute to nuclear DNA damage, especially at later time-points.

3) Summary

Acetaminophen (APAP) is only used as analgesic and antipyretic agent in therapeutic doses (15 mg/kg, three to four times per day). However, APAP overdose (a single dose of 150 mg/kg) causes hepatotoxicity (Brok et al., 2006). APAP is eliminated by sulfation and glucuronidation. A small portion of APAP is metabolized by cytochrome P450 isoenzymes that produce \(N\)-acetyl-\(p\)-benzoquinone imine (NAPQI). NAPQI is detoxified by glutathione (GSH), resulting in the depletion of this sulfhydryl compound. Subsequently, NAPQI covalently binds to cellular proteins (Nelson, 1990), including mitochondrial proteins. Mitochondrial proteins appear to be the most critical
targets of NAPQI leading to inhibition of mitochondrial respiration and causing oxidative stress, which eventually triggers the mitochondrial membrane permeability transition (MPT) (Kon et al., 2004). In addition, mitochondrial and nuclear DNA fragmentation is induced. These series of events results in extensive centrilobular liver necrosis (Figure 1.7).
Figure 1.7
Mechanism of acetaminophen-induced hepatotoxicity.
CHAPTER 2 : HYPOTHESIS AND AIMS

Acetaminophen (APAP) is a commonly used drug for the relief of fever and pain. However, an overdose of APAP is hepatotoxic. The mechanisms of APAP-induced liver injury have been studied extensively. Based on these findings, three protective strategies were investigated in detail:

Aim 1) Glutathione (GSH) and N-acetylcysteine (NAC)
Aim 2) Metallothionein (MT)
Aim 3) JNK inhibitor

Aim 1
NAC is used at very high doses both in humans and in experimental animals. These doses are higher than needed for the re-synthesis of hepatic GSH levels. However, our lab demonstrated that a moderate dose of GSH is highly effective in protecting against APAP toxicity. Therefore, I investigated whether there is a difference between the efficacy of NAC and GSH in protecting against APAP hepatotoxicity.

Aim 2
Metallothionein (MT) has been suggested to react with free radicals. APAP-induced hepatotoxicity studies showed a protective effect by MT. The modulation of APAP toxicity was independent of P450 levels and the metabolic activation of APAP. In contrast, the protection appeared to be correlated with the antioxidant function of MT. However, it remains unclear whether MT can actually scavenge reactive oxygen species (ROS) of APAP.
Thus, the objective of this study was to investigate the mechanism by which induction of MT expression protects against APAP-induced hepatotoxicity *in vivo*.

**Aim 3**

C-jun N-terminal kinase (JNK) has been suggested to contribute to APAP-induced liver injury. The postulated mechanism of JNK involvement was the promotion of mitochondrial Bax translocation, which triggers mitochondrial outer membrane pore formation resulting in the release of intermembrane proteins such as apoptosis inducing factor (AIF) and endonuclease G (EndoG). However, our laboratory reported that Bax-deficient mice were only temporally protected against APAP-induced liver injury (Bajt *et al.*, 2008). In contrast, the protective effect of JNK inhibitor was observed consistently up to 12 h. Therefore, additional mechanisms of injury need to be triggered by JNK activation, and tested the hypothesis that JNK promotes iNOS induction and mitochondrial oxidant stress.
CHAPTER 3: MATERIALS AND METHODS

3.1 Common methods

3.1.1 Experimental Protocols.

At selected times after APAP treatment, groups of animals were killed by cervical dislocation under isoflurane anesthesia. Blood was drawn from the vena cava into heparinized syringes and centrifuged. The plasma was used for determination of alanine aminotransferase (ALT) activities. Immediately after collecting the blood, the livers were excised and rinsed in saline. A small section from each liver was placed in 10% phosphate buffered formalin. The remaining liver was frozen in liquid nitrogen and stored at -80°C.

3.1.2. ALT.

Plasma ALT activities were determined with the kinetic test kit 68-B (Biotron Diagnostics, Inc., Hernet, CA) and expressed as IU/liter.

3.1.3 Subcellular fraction and protein concentrations.

The method is described in the manufacturer's instructions (Pierce, Rockford, IL). Mitochondria and cytosol were isolated using the mitochondria isolation kit for tissue (Pierce, Rockford, IL).

Protein in cytosol and mitochondria fraction was measured using the bicinchoninic acid kit (Pierce, Rockford, IL).

3.1.4 Western blotting.

Liver tissue was homogenized in 25 mM HEPES
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (pH 7.5) containing 5 mM EDTA, 2 mM DTT (dithiothreitol), 0.1% CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate), 1 mg/ml pepstatin, leupeptin, and aprotinin. Homogenates were centrifuged at 14,000 g at 4°C for 20 min. Cytosolic extracts (10 µg per lane) were resolved by 4–20% SDS–polyacrylamide gel electrophoresis under reducing conditions. Separated proteins were transferred to polyvinylidene difluoride membranes (PVDF, Immobilin-P, Millipore, Bedford, MA). For metallothionein, separated proteins were transferred to a polyvinylidene difluoride membrane (PVDF, Immobilon-PSQ Millipore, Bedford, MA), which is a special membrane for smaller molecular weight proteins. The membranes were first blocked with 5% milk in TBS (20 mM Tris, 154 mM NaCl, 0.1% Tween 20, and 0.1% BSA) overnight at 4°C, followed by incubation with primary antibody, e.g., a rabbit anti-Bax polyclonal antibody (Cell signaling Technology, Danvers, MA), a rabbit anti-AIF monoclonal antibody (Epitomics, Burlingame, CA), rabbit anti-Cytochrome c polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA), a monoclonal mouse anti-Metallothionein antibody (DAKO Corp., Carpinteria, CA) for 2 h at room temperature. The membranes were washed and then incubated with the secondary antibody with horseradish peroxidase (Santa Cruz Biotechnology). Proteins were visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech. Inc., Piscataway, NJ), according to the manufacturer’s instructions. Densitometric analysis of the
gels was performed with a GS170 Calibrated Imaging Densitometer (Biorad, Hercules, CA) using Quantity One 4.0.3 software (Biorad).

3.1.5 Total GSH and GSSG measurements.

Total soluble GSH and GSSG were measured in the liver homogenate and in isolated mitochondria with a modified method of Tietze as described (Jaeschke and Mitchell, 1990; Knight et al., 2002). Frozen tissues (or isolated mitochondria) were homogenized at 0°C in 3% sulfosalicylic acid containing 0.1 mM EDTA (Jaeschke and Mitchell, 1990). An aliquot of the homogenate was added to 10 mM N-ethylmaleimide (NEM) in potassium phosphate buffer (KPP), and another aliquot was added to 0.01 N HCl. The NEM-KPP sample was centrifuged, and the supernatant was passed through a C_{18} cartridge to remove free NEM and NEM-GSH adducts (Sep-Pak; Waters, Milford, MA). The HCl sample was centrifuged, and the supernatant was diluted with KPP. All samples were assayed using dithionitrobenzoic acid (DTNB). All data are expressed in GSH-equivalents.

3.1.6 Histology, TUNEL assay, immunohistochemistry for nitrotyrosine.

Formalin-fixed tissue samples were embedded in paraffin and 5 µm sections were cut. Replicate sections were stained with hematoxylin and eosin (H&E) for evaluation of necrosis (Gujral et al., 2002). For the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, sections of liver were stained with the In Situ Cell Death Detection Kit,
AP (Roche Diagnostics, Indianapolis, IN) as described in the manufacturer’s instructions (Gujral et al., 2002). Nitrotyrosine protein adducts were detected with standard immunohistochemical methods using an anti-nitrotyrosine antibody (Molecular Probes, Eugene, OR) (Knight et al., 2002).

3.1.7 Quantitative real-time polymerase chain reaction (qRT-PCR).

Total RNA was reversed transcribed with M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA) and oligo-dT primers (ABI Primer Express software, Foster City, CA).

The primer sequences for the genes examined are as follows:

β-actin:

Forward, 5’-GTATGACTCCACTCACGCAAA-3’,
Reverse, 5’-GGTCTCGCTCCTGGAAAGATG-3’,

MT-1:

Forward 5’-AATGTGCCCCAGGGCTGTGT-3’,
Reverse, 5’-GCTGGGTGTTGGTCGATACTATT,

MT-2:

Forward, CCTCACTGGCAGGAATCATC,
Reverse, 5’-CCTCGTGAGAGCGCTTTACA,

iNOS:

Forward, 5’-ACATCAGGTCGGCCATCACT3’,
Reverse, 5’-CGTACCGGATGAGCTGTGAATT-3’.
The SYBR green PCR Master Mix (Applied Biosystems, Foster City, CA) was used for real-time PCR analysis. The relative differences in gene expression between groups were expressed using cycle time (Ct) values. Ct values for the various genes were first normalized with that of β-actin in the same sample, and then relative differences between groups were expressed as relative increases setting control as 1.

3.1.8 Statistics.

Data are expressed as means ± S.E. Comparison between two groups were performed with Student's t-test or one-way ANOVA followed by Bonferroni t-test for multiple groups. If the data were not normally distributed, the Mann-Whitney test was applied for comparison of two groups and the Kruskal-Wallis Test (nonparametric ANOVA) followed by Dunn’s Multiple Comparisons Test for multiple groups. P<0.05 was considered significant.

3.2 Specific methods for Aim 1

3.2.1 Animals.

Male C3HeB/FeJ mice (8-10 weeks old) were purchased from Jackson Laboratories (Bar Harbor, ME). Animals received humane care according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals”. The experimental protocol was approved by the Institutional Animal Care and Use Committee of Kansas University Medical Center. The animals were fasted overnight and then received 300 mg/kg
APAP (Sigma Chemical Co., St. Louis, MO) dissolved in warm saline (15 mg/ml) (i.p.). Some animals received a single intravenous bolus dose of glutathione (200 mg/kg GSH; 0.65 mmol/kg) dissolved in phosphate-buffered saline (PBS), 106 mg/kg (0.65 mmol/kg) or 318 mg/kg (1.95 mmol/kg) N-acetyl cysteine, a mixture of 3 amino acids [49 mg/kg (0.65 mmol/kg) glycine, 96.4 mg/kg (0.65 mmol/kg) glutamic acid, and 106 mg/kg (0.65 mmol/kg) NAC] or a mixture of 2 amino acids [73.5 mg/kg (0.98 mmol/kg) glycine and 144.6 mg/kg (0.98 mmol/kg) glutamic acid]. All compounds were administered intravenously through the penile vein 1.5 h after APAP injection (Bajt et al., 2003; Cover et al., 2005b; Knight et al., 2002). The rationale for the treatment at 1.5 h is based on the assumption that by that time most of the administered APAP has been metabolized and most of the protein binding of NAPQI is completed.

3.2.2 NMR experiments.

For NMR experiments, further groups of mice were treated with APAP and the study substances at t = 1.5 h as mentioned above [GSH, NAC, a mixture of 3 amino acids (glycine, glutamate, cysteine), a mixture of 2 amino acids, or cysteine]. At t = 1.5 h or t = 6 h, all mice received [U-13C]glucose (500 mg/kg; 2.78 mmol/kg) (Cambridge Isotopes, Andover, MA), which was injected intraperitoneally in bolus to study metabolic changes in awake mice. Using 500 mg/kg [U-13C]glucose, plasma glucose was <10 mM in all experiments. The mice were killed by cervical dislocation and the livers
freeze-clamped immediately. Blood was taken after severing of the carotid artery and put into tubes containing heparin. Water-soluble metabolites were extracted from blood or tissue with perchloric acid and analyzed by NMR spectroscopy (Zwingmann and Bilodeau 2006).

3.3 Specific methods for Aim 2

3.3.1 Animals.

Male C57BL/6J mice (8-10 weeks old), male age-matched wildtype 129S1/SvImJ and male MT-1/MT-2 deficient mice (129S7/SvEvBrd-Mt1tm1Bri Mt2tm1Bri/J) were purchased from Jackson Laboratories (Bar Harbor, ME). Animals received humane care according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals”. The experimental protocol was approved by the Institutional Animal Care and Use Committee of Kansas University Medical Center. Some animals received a non-toxic dose of 100 µmol/kg zinc chloride (Fluka Chemical Corp., Milwaukee, WI) dissolved in saline (9.9 µmol/ml) subcutaneously once a day for 3 days (Liu et al., 2009). All animals were fasted overnight and on the 4th day, they received 300 mg/kg APAP (Sigma Chemical Co., St. Louis, MO) dissolved in warm saline (15 mg/ml) by intraperitoneal injection.

3.3.2 Mouse hepatocyte isolation.

Primary hepatocytes were isolated from overnight fasted mice with a standard collagenase procedure as previously described in detail (Bajt et al.,
Untreated and ZnCl₂-treated animals were used. Some of the animals were treated with 100 mg/kg phorone i.p. (Sigma) to deplete hepatic GSH levels 90 min before cell isolation. The GSH-depleted cells were then incubated in the presence of the GSH synthesis inhibitor buthionine sulfoximine (1 mM) (Sigma). From the isolation of one mouse liver, a typical yield was about 50–60 x10⁶ hepatocytes. Cell viability, as determined by trypan blue exclusion, was generally >90%, and cell purity was >95% hepatocytes. Cells were plated in six-well plates (6 x 10⁵ cells/well) (Biocoat collagen I cellware plates; Becton Dickinson) in Williams’ Medium E (Gibco) containing 10% fetal bovine serum (Gibco), 100 U/ml penicillin/streptomycin, and 1 x 10⁻⁷ M insulin and cultured at 37 °C in room air with 5% CO₂. After an initial 4 h attachment period, cultures were washed with phosphate-buffered saline (PBS) and then plain culture medium (controls) or media containing various concentrations of hydrogen peroxide were added. Cell injury was assessed by lactate dehydrogenase (LDH) release into the medium. LDH activities were measured as described (Bajt et al., 2004).

3.3.3 Analysis of MT-NAPQI interactions by mass spectrometry.

MT from rabbit liver was purchased from Sigma (M5269) as a lyophilized powder. The protein was suspended in deionized water to a protein concentration of 1 mg/ml. NAPQI was purchased from Sigma (A7300) and diluted in water to a final concentration of 12 µg/ml. For mass spectrometric measurements, protein samples were desalted on a C18
reverse phase column (Zorbax C18SB Wide pore guard Column, MicroTech Scientific, 1 cm x 0.32 mm), which was connected online to a valve to direct the flow either to waste or to the mass spectrometer (MS). After washing the column with 0.1% (v/v) TFA at a flow of 100 µl/min, the flow was directed to the mass spectrometer and the protein eluted using a 0-60% (v/v) acetonitrile gradient in 0.1% TFA at a flow rate of 20 µl/min. Electrospray ionization (ESI) MS data were acquired in the m/z range 800-2000 on a ThermoFinnigan LTQ FT. The mass spectrometer was under manual control to facilitate switching between two modes of data acquisition, on the Ion Trap (IT) and on the Ion Cyclotron Resonance Fourier Transform cell (ICR FT). Final optimized settings for detection of MT were: ion spray voltage 2.1 kV, capillary temperature 250 °C, capillary voltage 34V. The two modes of operation have different sensitivity and mass resolution. The charge state of all protein species detected was calculated from the isotopic distribution of the high resolution spectrum obtained in the ICR FT. However, due to the higher sensitivity of the IT, data reported here are for the acquisition on the IT. Masses of the different protein variants were calculated from the multiple charged protein ions using the deconvolution software included in BioworksBrowser V. 3.1 (ThermoFinnigan). The resulting masses were measured with an experimental precision of ± 1.5 dalton.
3.4 Specific methods for Aim 3

3.4.1 Animals.

Male C57BL/6J mice (8-10 weeks old), JNK2-deficient mice (B6.129S2-Mapl9tm1Flv/J or age-matched wild type (C57Bl/6J) mice were purchased from Jackson Laboratories (Bar Harbor, ME). Animals received humane care according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals”. The experimental protocol was approved by the Institutional Animal Care and Use Committee of the Kansas University Medical Center.

3.4.2 Experimental Protocols.

All animals were fasted overnight and some animals received a JNK inhibitor, 10 mg/kg SP600125 (LC Laboratories) dissolved in 8.3 % DMSO in PBS (1 mg in 125 μl of DMSO diluted with 1375 μl of PBS) (Hanawa et al., 2008). JNK inhibitor and DMSO, unless noted otherwise, were injected intraperitoneally 1 h prior to 600 mg/kg APAP injection (Sigma Chemical Co., St. Louis, MO). Some animals received 300 mg/kg APAP with either 0.65 mmol/ kg GSH (i.v.) administration at 1.5h after APAP or 100 μmol/kg ZnCl2 administration for 3 days. APAP was dissolved in warm saline (15 mg/ml). Some animals received 2 mg/kg ip lipopolysaccharide (Sigma), with/without 3.3 mg/kg ip L-N-(1-iminoethyl)lysine (L-Nil) (Cayman) at 0 and 3 h.

3.4.3 Measurement of Nitrite/nitrate in plasma.

The plasma concentrations of nitrite/nitrate were determined with a kit.
(Cayman) by means of the Griess reaction.
4.1 Abstract.

Acetaminophen (APAP) overdose is a major cause of acute liver failure. The glutathione (GSH) precursor $N$-acetylcysteine (NAC) is used to treat patients with APAP overdose for up to 48 h. Although it is well established that early treatment with NAC can improve the scavenging of the reactive metabolite $N$-acetyl-p-benzoquinone imine (NAPQI), protective mechanisms at later times remain unclear. To address this issue, fasted C3Heb/FeJ mice were treated with 300 mg/kg APAP and then received intravenously 0.65 mmol/kg GSH or NAC at 1.5 h after APAP. The animals were sacrificed at 6 h. APAP alone caused severe liver injury with peroxynitrite formation and DNA fragmentation, all of which were attenuated by both treatments. However, GSH (-82%) was more effective than NAC (-46%) in preventing liver injury. Using nuclear magnetic resonance spectroscopy to measure tissue ATP levels and the substrate flux through the mitochondrial Krebs cycle, it was observed that the reduced liver injury correlated with accelerated recovery of mitochondrial GSH content, maintenance of ATP levels and an increased substrate supply for the mitochondrial Krebs cycle compared to APAP alone. NAC treatment was less
effective in recovering ATP and mitochondrial GSH levels and showed reduced substrate flux through the Krebs cycle, compared to GSH. However, increasing the dose of NAC improved the protective effect similar to GSH suggesting that the amino acids not used for GSH synthesis were used as mitochondrial energy substrates. Taken together, delayed treatment with GSH and NAC protect against APAP overdose by dual mechanisms, i.e. by enhancing hepatic and mitochondrial GSH levels (scavenging of reactive oxygen species and peroxynitrite) and by supporting the mitochondrial energy metabolism.

4.2 Introduction.

Acetaminophen (APAP) is a safe analgesic at therapeutic levels. However, an overdose can cause severe liver injury and even acute liver failure. During the last decade, APAP became the most frequent cause of acute liver failure in the US and many other countries (Larson et al., 2005). Early animal studies established the formation of the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), which first depletes glutathione and subsequently binds to proteins, critical events in APAP toxicity (Jollow et al., 1973; Mitchell et al., 1973a; Mitchell et al., 1973b). Based on this mechanistic insight, N-acetylcysteine (NAC) was introduced to treat patients with APAP overdose in the 1970s (Prescott et al., 1977). Even today, NAC therapy is still the best therapeutic option for the overdosed patient (Polson and Lee, 2005).
NAC is most effective when given as early as possible after APAP intoxication. The main mechanism of action of NAC is to promote hepatic GSH synthesis (Corcoran and Wong, 1986; Lauterburg et al., 1983), which supports the detoxification of NAPQI and reduces protein binding (Corcoran et al., 1985). However, NAC therapy is clinically effective even when initiated 24 h after APAP overdosing, i.e. at a time when there is no relevant amount of drug left to be metabolized (Harrison et al., 1990; Smilkstein et al., 1988). These observations suggest that there might be other, yet unknown mechanisms of protection. This hypothesis is also supported by the fact that NAC can protect in models without GSH depletion (Zwingmann and Bilodeau, 2006). Recent insight into the molecular mechanisms of APAP-induced hepatotoxicity in a mouse model indicated that the early protein binding is an essential initiating event, which requires intracellular propagation and amplification (Jaeschke and Bajt, 2006; Jaeschke et al., 2003). Key to this propagation mechanism is mitochondrial dysfunction and oxidant stress (Jaeschke and Bajt, 2006). Intravenous administration of GSH after APAP treatment resulted in the accelerated recovery of GSH in the mitochondria (Knight and Jaeschke, 2002). The elevated levels of mitochondrial GSH effectively scavenged reactive oxygen and peroxynitrite, which reduced APAP-induced liver injury and promoted regeneration (Bajt et al., 2003; Cover et al., 2005b; Knight and Jaeschke, 2002). Delayed treatment with NAC had a similar protective effect (James et al., 2003c). These findings support the hypothesis that the delayed
supply of cysteine can be involved in a second mechanism of protection, i.e. the scavenging of reactive oxygen species and peroxynitrite (Jaeschke and Bajt, 2006; Jaeschke et al., 2003). The dose of GSH we used in our recent experiments (Bajt et al., 2003; Cover et al., 2005b; Knight and Jaeschke, 2002) was based on previous data showing its efficacy in supporting the recovery of hepatic GSH levels after starvation (Wendel and Jaeschke, 1982). This dose provides enough cysteine to re-synthesize twice the entire GSH content of a mouse liver. However, in most studies with NAC, generally much higher doses are used, e.g. 300 – 1200 mg/kg of NAC (Corcoran et al., 1985; James et al., 2003c; McConnachie et al., 2007; Salminen et al., 1998; Whitehouse et al., 1985), which is sufficient to synthesize the hepatic GSH content between 6 and 23 times. For treatment of acute APAP poisoning in patients, the recommended dose for NAC is a 150 mg/kg loading dose followed by maintenance doses of 50 mg/kg every 4 h (Polson and Lee, 2005). Again, even the loading dose alone would be sufficient cysteine to synthesize several times the entire hepatic GSH content. This raises the question whether GSH is more effective than NAC, or if there are additional benefits of high doses of NAC that have not been considered. To address this important question, we compared the efficacy and mechanisms of protection of equimolar doses of GSH and NAC in a murine model of APAP hepatotoxicity.
4.3 Results.

**GSH treatment was most effective in preventing APAP-induced liver injury.** Male C3Heb/FeJ mice treated with an overdose of APAP (300 mg/kg) showed evidence of severe liver injury at 6 h as indicated by increases in plasma ALT values (Figure 4.1.A). In addition, there was only a partial recovery of the hepatic GSH content and evidence of oxidant stress, as indicated by the elevated levels of hepatic GSSG and increased GSSG-to-GSH ratio (Figure 4.1 B-D). Treatment of mice with equimolar doses of GSH or NAC (0.65 mmol/kg) at 1.5 h after APAP resulted in reduced increases in plasma ALT. (Figure 4.1 A). However, GSH treatment was more effective in preventing APAP-induced liver injury as indicated by the 82% lower ALT values compared to the 46% reduction with NAC. However, both treatments resulted in a complete recovery of hepatic GSH levels (Figure 4.1 B). The hepatic GSSG content was further increased in the GSH and NAC treated mice, compared to APAP alone. However, the GSSG-to-GSH ratio was similar in all APAP-treated groups (Figure 4.1 D). These results suggest that ROS are still being formed after GSH or NAC treatment but this oxidant stress is more efficiently detoxified due to the higher GSH levels. The biochemical data was confirmed by histological findings. H&E staining of liver sections indicated the substantial centrilobular necrosis 6 h after APAP administration (Figure 4.2). The loss of basophilic staining, vacuolization, cell swelling and karyolysis around the centrilobular veins documents that the
cells undergoing oncotic necrosis (Figure 4.7). The extent of necrosis correlated with massive DNA fragmentation, as demonstrated by the TUNEL assay and peroxynitrite formation, as indicated by the presence of nitrotyrosine protein adducts in the centrilobular areas (Figure 4.2). Delayed treatment with GSH markedly reduced the area of necrosis, nitrotyrosine protein adducts as well as the number of TUNEL-positive cells (Figure 4.2; Figure 4.7). Treatment with NAC also attenuated the areas of necrosis, nitrotyrosine staining and the extent of DNA damage (Figure 4.2). However, the protective effect of NAC was less pronounced compared than GSH. Together, these results suggest that treatment with GSH 1.5 h after APAP administration was more effective in protecting the liver compared to an equimolar dose of NAC. Because hepatic GSSG levels further increased after GSH or NAC treatment compared to APAP alone, this indicates that ROS are more effectively detoxified but are still being formed. Thus, both delayed treatments did not affect the oxidant stress induced by APAP overdose (Figure 4.1C,D).

**GSH and NAC treatment had similar effects on early GSH recovery.**

Although there was a clear difference in tissue injury between the GSH- and the NAC-treated groups, based on the GSH and GSSG data of the 6 h time point (Figure 4.1), it appears that the efficacy in supplying cysteine for recovery of hepatic GSH levels and scavenging reactive oxygen was similar between the 2 treatment groups. To verify that this conclusion is justified, a
more detailed time course of the depletion and recovery of hepatic GSH levels was studied (Figure 4.3 A). Treatment with APAP resulted in an 86% depletion of hepatic GSH levels within 30 min and no further decline thereafter (Figure 4.3 A). When saline was injected 1.5 h after APAP, there was no immediate recovery of the GSH content. However, between 2.5 and 4 h, GSH levels spontaneously recovered to about 70% of baseline, with no further improvement thereafter (Figure 4.3 A). In contrast, injection of GSH or NAC resulted in a rapid and complete recovery of hepatic GSH levels within 1 h and an additional increase over the next 1.5 h (Figure 4.3 A). Despite the similar recovery of the hepatic GSH content, plasma ALT values indicated improved protection in the GSH-treated animals compared to NAC (Figure 4.3 B). Because our previous studies identified the mitochondria as the main source of oxidant stress and peroxynitrite formation (Cover et al., 2005b; Jaeschke, 1990; Knight et al., 2001; Tirmenstein and Nelson, 1990), the mitochondrial GSH content was evaluated 45 min after the injection of GSH or NAC (Figure 4.3 C). Compared to an untreated control, mitochondrial GSH levels are still 90% depleted 2.25 h after APAP exposure. Injection of GSH resulted in a complete recovery of mitochondrial GSH levels (Figure 4.3 C). However, injection of an equimolar dose of NAC caused only a partial recovery of the mitochondrial GSH content to levels 34% below controls or GSH-treated animals (Figure 4.3 C). These results indicate that the supply of cysteine through GSH or NAC is sufficient to re-synthesize GSH in the cytosol.
but there is a delay of the energy-dependent transport of GSH into the mitochondria with NAC.

**Hepatic energy status and metabolism.**

It is well established that APAP-induced hepatotoxicity causes mitochondrial dysfunction with depletion of hepatic ATP levels (Jaeschke, 1990; Kon et al., 2004; Tirmenstein and Nelson, 1990). In addition, it was recently shown that high levels of NAC can improve mitochondrial energy metabolism (Zwingmann and Bilodeau, 2006). Therefore, we hypothesized that the difference between GSH and NAC treatment might be caused by differential effects on mitochondrial energy metabolism. Using NMR, we compared changes in ATP levels with alterations in mitochondrial energy metabolism. We chose to evaluate these parameters at two time points, an early time (2.25 h) during the initiation of the injury and a late time (6.75 h) when substantial necrosis was evident. As a measure of the hepatocellular energy state, the concentrations of ATP were determined from $^{31}$P-NMR spectra of liver extracts (Figure 4.4). ATP levels in the livers of mice treated with APAP were reduced to 66% and 42% of saline-treated controls at the early and late time point, respectively. Whereas ATP levels were not significantly different from controls after administration of GSH at both time-points, treatment with NAC did not result in an early ATP recovery, and improved the energy status only partially (to 70% of controls) at the late time point.

**GSH causes early and late upregulation of mitochondrial energy**
Two pathways mediate the entry of carbon from $[\text{U-}^{13}\text{C}]$glucose into the Krebs cycle after conversion to $[\text{U-}^{13}\text{C}]$pyruvate (Figure 4.5 A): 1) Pyruvate dehydrogenase (PDH), which converts pyruvate into acetyl-CoA and is considered the key enzyme for mitochondrial energy metabolism. 2) Pyruvate carboxylase (PC) converts pyruvate into the Krebs cycle intermediate oxaloacetate, which needs to combine with acetyl-CoA to allow for synthesis of amino acids such as glutamate. Oxaloacetate can also be replenished after anaplerotic entry of other substrates to the Krebs cycle, such as the glutamate residue in GSH. Therefore, we administered GSH or NAC together with $[\text{U-}^{13}\text{C}]$glucose 1.5 h after APAP treatment. Additional GSH/NAC treated animals were injected with $[\text{U-}^{13}\text{C}]$glucose at 6 h. Figure 4.5 shows the amounts of $^{13}\text{C}$-labelled glutamate (C-4 position), formed through PDH from $[\text{U-}^{13}\text{C}]$glucose (Figure 4.5 D,E), as well as of the Krebs cycle intermediate succinate (Figure 4.5 B,C). Despite ATP depletion, treatment of mice with APAP did not result in a diminished flux through PDH with reduced succinate or glutamate formation at both time points (Figure 4.5 B-E). However, administration of GSH to APAP-treated mice caused a significantly augmented formation of both $^{13}\text{C}$-labelled glutamate and succinate (more than 4-fold and 2-fold elevation at 2.25 h, respectively), which supports early mitochondrial ATP formation (Figure 4.5 B,D). The stimulating effects on glutamate and succinate formation could still be observed 6.75 h after APAP
administration (Figure 4.5 C,E). The effects of NAC were much less pronounced compared to GSH at 2.25 h (Figure 4.5 B,D) and disappeared at 6.75 h (Figure 4.5 C,E).

**High doses of NAC effectively protect against APAP hepatotoxicity.**

To evaluate if the difference between GSH and NAC in protecting against APAP toxicity is caused by the different amount of amino acids administered, 3 times higher doses of NAC were injected and the efficacy compared to the 3 individual amino acids of GSH (glutamate, glycine and cysteine) and to a similar dose of only 2 amino acids (glutamate, glycine). Both, the high dose of NAC and the 3 amino acids were more effective than the low NAC group in protecting against APAP-induced toxicity (Figure 4.6 A) and in maintaining liver ATP levels at early and later time points (Figure 4.6 C,D). All three treatments were equally effective in restoring total hepatic GSH levels (Figure 4.6 B). In contrast, treatment with 2 amino acids (lack of cysteine) did not improve the recovery of hepatic GSH levels and failed to protect despite the partial improvement of hepatic ATP levels (Figure 4.6 A-D). The substrate flux through the Krebs cycle correlated with ATP formation in the different treatment groups (Figure 4.8).
Figure 4.1
Figure 4.1

Plasma alanine aminotransferase (ALT) activities (A) and the hepatic content of glutathione (GSH+GSSG) (B) and glutathione disulfide (GSSG) (C) were quantified in control animals or mice treated with 300 mg/kg acetaminophen (APAP) for 6 h. The ratio between GSSG and total glutathione was calculated (D). Some of the animals received additionally 10 ml/kg saline, 0.65 mmol/kg GSH or 0.65 mmol/kg N-acetylcysteine (NAC) iv 1.5 h after APAP. Data represent means ± SE of n = 5 animals per group. *P<0.05 (compared to controls); #P<0.05 (compared to APAP/saline)
Figure 4.2
Figure 4.2

Histological assessment of liver injury (hematoxilin & eosin, H&E), peroxynitrite formation (nitrotyrosine staining) and DNA fragmentation (TUNEL assay) in control animals or mice treated with 300 mg/kg acetaminophen (APAP) for 6 h. Some of the animals received additionally 10 ml/kg saline, 0.65 mmol/kg GSH or 0.65 mmol/kg N-acetylcysteine (NAC) iv 1.5 h after APAP. The representative pictures show extensive centrilobular necrosis, which correlated with the areas of nitrotyrosine staining and TUNEL-positive cells in APAP-treated animals. Both, GSH and NAC treatment improved all parameters with GSH being more effective than NAC. (x100 for all panels)
Figure 4.3
Figure 4.3

Time course of hepatic glutathione (GSH+GSSG) levels (A) and plasma ALT activities (B) after treatment with 300 mg/kg APAP. Some animals received additionally 10 ml/kg saline, 0.65 mmol/kg GSH or 0.65 mmol/kg N-acetylcysteine (NAC) iv 1.5 h after APAP. Data represent means ± SE of n = 4 animals per time point. *P<0.05 (compared to APAP/saline); #P<0.05 (compared to APAP/GSH). Mitochondrial glutathione content in controls or 2.5 h after injection of APAP alone or in combination with GSH and NAC (C). Data represent means ± SE of n = 4 animals per group or time point. *P<0.05 (compared to controls, C); #P<0.05 (compared to APAP/GSH).
Figure 4.4
Figure 4.4

Tissue concentrations of ATP (µmol/g wet weight), as calculated from its resonances in $^{31}$P-NMR spectra of liver extracts. The mice were treated with 300 mg/kg APAP and some subsequently received 0.65 mmol/kg GSH or NAC at 1.5 h after APAP. ATP levels were measured 2.25 h (A) or 6.75 h (B) after treatment with APAP. Data represent means ± SE of n = 4 animals per group. *P<0.05 (compared to controls, C); #P<0.05 (compared to APAP/GSH)
Figure 4.5
Figure 4.5
Labeling of glutamate from [U-\(^{13}\)C]glucose. [U-\(^{13}\)C]glucose is first metabolized to \([3-^{13}\)C]pyruvate, which is converted via pyruvate dehydrogenase (PDH) and pyruvate carboxylase (PC) to \([2-^{13}\)C]acetyl-CoA and \([3-^{13}\)C]oxaloacetate, respectively. The fluxes through PDH and PC lead to a different \(^{13}\)C-labeling pattern in the Krebs cycle intermediate citrate, and are finally measured by the isotopomer pattern of glutamate in \(^{13}\)C-NMR spectra (A). Concentrations of \(^{13}\)C-labelled \([4,5-^{13}\)C]glutamate and the Krebs cycle intermediate \([2,3-^{13}\)C]succinate (nmol/g wet weight), as calculated from their resonances in \(^1\)H- and \(^{13}\)C-NMR spectra of liver extracts. The mice were treated with 300 mg/kg APAP and some subsequently received 0.65 mmol/kg GSH or NAC at 1.5 h after APAP. Glutamate (D,E) and succinate (B,C) levels were measured 45 min after injection of [U-\(^{13}\)C]glucose, i.e. at 2.25 h after APAP (B,D) or 45 min after injection of [U-\(^{13}\)C]glucose, i.e. 6.75 h after APAP (C,E). Data represent means ± SE of \(n = 4\) animals per group. *P<0.05 (compared to controls, C); #P<0.05 (compared to APAP/GSH)
Figure 4.6
Figure 4.6

Plasma alanine aminotransferase (ALT) activities (A) and the hepatic content of glutathione (GSH+GSSG) (B) were measured in mice treated with 300 mg/kg acetaminophen (APAP) for 6 h. Some of the animals received additionally 10 ml/kg saline, 0.65 mmol/kg N-acetylcysteine (l-NAC), 1.95 mmol/kg NAC (h-NAC), a mixture of 3 amino acids (0.65 mmol/kg of glycine, glutamic acid and NAC) (3AS) or a mixture of 2 amino acids (0.98 mmol/kg glycine and glutamic acid) (2AS) iv 1.5 h after APAP. Data represent means ± SE of n = 5 animals per group. *P<0.05 (compared to controls); #P<0.05 (compared to APAP/saline). Tissue concentrations of ATP (µmol/g wet weight) (C, D), as calculated from its resonances in 31P-NMR spectra of liver extracts. The mice were treated as under A-B and ATP levels were measured 2.25 h (C) or 6.75 h (D) after treatment with APAP. Data represent means ± SE of n = 4 animals per group. *P<0.05 (compared to APAP/saline)
Figure 4.7
Figure 4.7
Histological assessment of liver injury (hematoxilin & eosin, H&E) in control animals or mice treated with 300 mg/kg acetaminophen (APAP) for 6 h. Some of the animals received additionally 10 ml/kg saline, 0.65 mmol/kg GSH or 0.65 mmol/kg Nacetylcysteine (NAC) iv 1.5 h after APAP. The representative pictures show extensive centrilobular necrosis as indicated by the loss of basophilic staining, vacuolization, cell swelling and karyolysis in APAP-treated animals. Both, GSH and NAC treatment improved the area of necrosis with GSH being more effective than NAC. (x200 for all panels)
Figure 4.8
Figure 4.8
Concentrations of $^{13}$C-labelled $[4,5-^{13}$C$]$glutamate and the Krebs cycle intermediate $[2,3-^{13}$C$]$succinate (nmol/g wet weight), as calculated from their resonances in $^1$H- and $^{13}$CNMR spectra of liver extracts. The mice were treated with 300 mg/kg APAP and some subsequently received additionally 10 ml/kg saline, 0.65 mmol/kg $N$-acetylcysteine ($l$-NAC), 1.95 mmol/kg NAC ($h$-NAC), a mixture of 3 amino acids (0.65 mmol/kg of glycine, glutamic acid and NAC) (3AS) or a mixture of 2 amino acids (0.98 mmol/kg glycine and glutamic acid) (2AS) iv 1.5 h after APAP. Data represent means ± SE of n =5 animals per group. *P<0.05 (compared to controls)
4.4 Discussion

The objectives of this investigation were to evaluate whether there is a difference in the efficacy to protect against APAP hepatotoxicity between GSH and clinically relevant doses of NAC, and to assess the mechanisms of this protection. The present data indicate that when animals are treated with low equimolar doses of GSH or NAC, GSH is more effective due to the higher amounts of amino acids, which are not only used to re-synthesize hepatic GSH but are also metabolized to serve as energy substrates in the Krebs cycle. This difference in protection between GSH and NAC can be eliminated if higher doses of NAC are used.

**Mechanisms of protection I: preventing covalent binding.**

The best established and most effective mechanism of protection by GSH or NAC is to enhance the scavenging capacity for NAPQI in hepatocytes. This prevents covalent modification of cellular proteins and thereby blocks the initiation of APAP toxicity (Corcoran et al., 1985; Lauterburg et al., 1983). Intravenously administered GSH is rapidly degraded in the kidney with a half-life in plasma of <2 min and the individual amino acids are re-absorbed (Wendel and Jaeschke, 1982). NAC or the amino acids of GSH are taken up into hepatocytes and are being used for re-synthesis of hepatocellular GSH, which is consumed by conjugation with NAPQI (Corcoran et al., 1985; Corcoran and Wong, 1986; Lauterburg et al., 1983). Despite the capacity of NAC to directly react with NAPQI, it has been clearly demonstrated that the
protection of NAC or GSH against APAP overdose requires the synthesis of GSH (Corcoran et al., 1985; Corcoran and Wong, 1986; Lauterburg et al., 1983; Wendel and Jaeschke, 1982). However, in order to be effective through this mechanism, GSH or NAC has to be administered during the metabolism phase of APAP toxicity. The delayed presentation of overdose patients to the emergency room can limit the efficacy of NAC through this mechanism.

**Mechanisms of protection II: scavenging of reactive oxygen species and peroxynitrite.** Covalent binding of NAPQI to mitochondrial proteins is a critical step that links the metabolic activation of APAP to the mitochondrial dysfunction (Nelson, 1990). This leads to inhibition of mitochondrial respiration with enhanced formation of reactive oxygen species and peroxynitrite in mitochondria (Cover et al., 2005b; Jaeschke, 1990; Knight et al., 2001; Tirmenstein and Nelson, 1990). The oxidant stress can directly trigger the mitochondrial membrane permeability transition pore opening with collapse of the mitochondrial membrane potential (Kon et al., 2004). In addition, the oxidant stress can activate the cjun N-terminal kinase, which can translocate to the mitochondria and facilitate the mitochondrial membrane permeability transition pore opening (Hanawa et al., 2008). Either mechanism assumes a critical role of mitochondrial reactive oxygen species and peroxynitrite formation in the pathophysiology. The toxicity of these reactive oxygen and reactive nitrogen species is potentiated by the fact that mitochondrial GSH levels are severely depleted during APAP metabolism,
which leaves these cell organelles highly vulnerable (Knight et al., 2001). Thus, delayed treatment with GSH or NAC can accelerate the recovery of mitochondrial GSH levels and scavenge reactive oxygen and reactive nitrogen species (James et al., 2003c; Knight et al., 2002). Despite the initial covalent binding, this treatment limits cellular necrosis, improves survival and facilitates repair of the damaged tissue (Bajt et al., 2003). Thus, a critical second mechanism of protection by NAC and GSH is the protection against oxidant stress and peroxynitrite specifically in mitochondria.

**Mechanisms of protection III: mitochondrial energy substrates.** The higher efficacy of GSH versus an equimolar dose of NAC in protecting against APAP suggests the involvement of a third mechanism. As was shown, both GSH and NAC provide enough cysteine to allow for an effective re-synthesis of the depleted cellular GSH levels. However, two critical differences between GSH- and NAC-treated animals emerged. First, cellular ATP levels were significantly better preserved with GSH treatment than with NAC. Based on the higher substrate supply for the Krebs cycle, this was most likely caused by the use of the excess amino acids not needed for GSH synthesis as energy substrates. The higher ATP levels support energy-requiring cellular functions including the maintenance of ion gradients by Na⁺/K⁺-ATPase and Ca²⁺-ATPase. Dysfunction of these enzymes has been implicated in necrotic cell death (Carini et al., 1995; Tsokos-Kuhn et al., 1988). Although the Km of ATP for transporters and enzymes is lower than the declining tissue ATP
levels after APAP treatment, it needs to be kept in mind that these concentrations represent the average in tissue homogenates, which includes healthy as well as dying cells. Thus, one would expect that ATP levels in cells of the centrilobular area are much lower than the average, and may well be in the range of the Km for ATP-dependent transporters and enzymes. In addition, the improved energy supply to mitochondria may be responsible for the accelerated uptake of cytosolic GSH into mitochondria, as was observed after GSH treatment. GSH is transported into mitochondria by the dicarboxylate carrier and the oxoglutarate carrier, which mediate electroneutral exchange of dicarboxylates for inorganic phosphate and 2-oxoglutarate for other dicarboxylates, respectively (Fernandez-Checa and Kaplowitz, 2005; Lash, 2006; Zhong et al., 2008). During the post-metabolism phase of APAP toxicity, mitochondrial GSH is most critical for the effective scavenging of reactive oxygen species and specifically peroxynitrite (Knight et al., 2002). The higher mitochondrial GSH levels and the reduced areas of nitrotyrosine staining correlated with the reduced areas of necrosis after GSH compared to NAC treatment. Supply of cysteine without providing additional energy substrates leads to sub-optimal protection as was observed with NAC treatment. However, supply of excess amino acids without cysteine leads to a partial recovery of ATP levels without GSH synthesis, but fails to prevent liver cell necrosis. This indicates that just supporting mitochondrial energy metabolism alone is insufficient to prevent cell death. These data extend previous data.
obtained on the effects of NAC and GSH in non-acetaminophen toxicity in mice. In particular, NAC significantly increased the flux through PDH, an effect which has been shown to be uncoupled from GSH synthesis, and was associated with the prevention of liver injury induced by tert-butylhydroperoxide and 3-nitropropionic acid. This study also showed that NAC has a limited capacity to increase GSH de novo synthesis, but that the administration of the GSH precursor cysteine alone in equimolar concentrations to NAC does not protect from a disturbed mitochondrial energy metabolism (Zwingmann and Bilodeau, 2006). The present study provides evidence that injection of GSH itself or of excess amino acids in APAP-treated animals clearly results in a better recovery of ATP levels. It further suggests a dual role of GSH supplementation in prevention of mitochondrial energy failure together with cellular GSH supply. This would also explain the higher efficiency when increasing the NAC doses and therefore of the amino acid cysteine. Thus, based on these observations it can be concluded that a combination of cysteine supply for glutathione synthesis and excess amino acids for metabolism in the Krebs cycle provides the most effective protection against APAP-induced mitochondrial dysfunction and necrotic cell death during the later, postmetabolism phase of the injury. This effect can be achieved by injection of either GSH or NAC in sufficient quantities. Although the present data show that at a dose of 0.65 mmol/kg GSH is more effective than NAC, the effect is clearly caused by the 3-fold
higher amount of amino acids injected with GSH compared to an equimolar dose of NAC. In fact, a 3-fold higher dose of NAC shows equally effective protection as with GSH or the mixture of the individual amino acids of GSH. Because the practice guidelines for the use of NAC recommend much higher doses than would be needed for the re-synthesis of hepatic GSH levels alone (Polson and Lee, 2005), our data suggest that the reason for the efficacy of high doses of NAC at these later time points is caused by recovery of hepatic and in particular mitochondrial GSH levels, and the improved mitochondrial bioenergetics.

In summary, our data indicate that the amino acids supplied with the delayed treatment of GSH or NAC are being used for the re-synthesis of hepatic glutathione levels, which protect against cell injury by scavenging reactive oxygen species and peroxynitrite in mitochondria. However, excess amino acids, i.e. amino acids not used for GSH synthesis, serve as energy substrates for the Krebs cycle and support the improved maintenance of hepatic ATP levels. Thus, the optimal protection by delayed GSH or NAC treatment involves the combination of two mechanisms, i.e., the accelerated recovery of mitochondrial GSH levels and support of the mitochondrial bioenergetics. These new findings provide the rationale for the clinical use of high doses of NAC well beyond the metabolism of APAP. In addition, these data suggest that more effective substrates for the mitochondrial energy metabolism than excess NAC may further limit cell death and improve
regeneration after APAP overdose.
CHAPTER 5: MECHANISM OF PROTECTION BY METALLOTHIONEIN AGAINST ACETAMINOPHEN HEPATOTOXICITY

5.1 Abstract.

Acetaminophen (APAP) overdose is the most frequent cause of drug-induced liver failure in the US. Metallothionein (MT) expression attenuates APAP-induced liver injury. However, the mechanism of this protection remains incompletely understood. To address this issue, C57BL/6 mice were treated with 100 µmol/kg ZnCl$_2$ for 3 days to induce MT. Twenty-four hours after the last dose of zinc, the animals received 300 mg/kg APAP. Liver injury (plasma ALT activities, area of necrosis), DNA fragmentation, peroxynitrite formation (nitrotyrosine staining), MT expression, hepatic glutathione (GSH) and glutathione disulfide (GSSG) levels were determined 6 h after APAP alone caused severe liver injury with oxidant stress (increased GSSG levels), peroxynitrite formation and DNA fragmentation, all of which were attenuated by zinc-induced MT expression. In contrast, MT knockout mice were not protected by zinc. Hydrogen peroxide-induced cell injury in primary hepatocytes was dependent only on the intracellular GSH levels but not on MT expression. Thus, the protective effect of MT in vivo was not due to the direct scavenging of reactive oxygen species and peroxynitrite. Zinc treatment had no effect on the early GSH depletion kinetics after APAP administration, which is an indicator of the metabolic activation of APAP to its reactive metabolite.
N-acetyl-p-benzoquinoneimine (NAPQI). However, MT was able to effectively trap NAPQI by covalent binding. We conclude that MT scavenges some of the excess NAPQI after GSH depletion and prevents covalent binding to cellular proteins, which is the trigger for the propagation of the cell injury mechanisms through mitochondrial dysfunction and nuclear DNA damage.

5.2 Introduction.

Acetaminophen (APAP) is a widely used analgesic and antipyretic drug. Although safe at therapeutic levels, an overdose can cause severe liver injury in animals and in humans (Larson et al., 2005). The toxicity is dependent on the metabolic activation of APAP via cytochrome P-450, which results in the formation of an electrophilic reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI) (Nelson, 1990). NAPQI is rapidly conjugated with glutathione (GSH) and the GSH-APAP adduct is excreted mainly into bile (Nelson, 1990). However, after the cellular GSH content is exhausted, NAPQI covalently binds to cellular proteins (Cohen and Khairallah, 1997; Jollow et al., 1973) including mitochondrial proteins (Qiu et al., 2001; Tirmenstein and Nelson, 1989). This covalent binding is thought to be responsible for the mitochondrial dysfunction observed after APAP overdose, including inhibition of mitochondrial respiration, ATP depletion, release of intermembrane proteins, and mitochondrial oxidant stress and peroxynitrite formation (Jaeschke and Bajt, 2006). The characteristic nuclear DNA damage
after APAP overdose (Ray et al., 1990) is initially linked to mitochondrial Bax translocation (Bajt et al., 2008) and later to oxidant stress/peroxynitrite formation and mitochondrial dysfunction (Cover et al., 2005b). The opening of mitochondrial membrane permeability transition (MPT) pores with collapse of the membrane potential and declining ATP levels (Kon et al., 2004) together with the extensive nuclear DNA damage (Shen et al., 1991) are the main reasons for the massive oncotic necrotic cell death after APAP overdose (Gujral et al., 2002). In addition to the intracellular signaling pathways of APAP-induced liver injury, a potential contribution of inflammatory cells is extensively but controversially discussed (Jaeschke, 2005, 2008; Liu et al., 2006). For example, investigations into the role of neutrophils yielded opposite results using the same neutropenia-inducing antibody (Cover et al., 2006; Liu et al., 2006). We suggested that the different results were caused by the prolonged pretreatment regimen in one of the studies that lead to a preconditioning effect with induction of several acute phase genes, in particular metallothionein (MT) (Jaeschke and Liu, 2007). Upregulation of any of these genes rather than neutropenia could have been the reason for the protection of the anti-neutrophil antibody. However, in order to address this complex problem, it is necessary to understand the mechanism by which some of these individual genes including MT could protect against APAP-induced hepatotoxicity.
MT, a ubiquitous heavy metal binding and cysteine-rich protein (Klaassen et al., 1999), has been suggested to react with free radicals and organic electrophiles (Cagen and Klaassen, 1980). Studies of APAP hepatotoxicity demonstrated enhanced liver injury and mortality in metallothionein-deficient mice (Liu et al., 1999; Rofe et al., 1998). In addition, induction of MT attenuated APAP-induced liver injury (Chengelis et al., 1986; Szymanska et al., 1991). The modulation of toxicity was independent of the P450 levels and the metabolic activation of APAP (Liu et al., 1999; Rofe et al., 1998). In contrast, the protection appeared to be correlated with an antioxidant function of MT (Liu et al., 1999). However, no direct evidence for this mechanism exists in vivo. In particular, it remains unclear whether MT can actually scavenge reactive oxygen species (ROS) and peroxynitrite, which are critical mediators of MPT and cell death (Jaeschke et al., 2003). Thus, the main objective of this investigation was to investigate the mechanism by which induction of MT gene expression may protect against APAP hepatotoxicity in vivo.

5.3 Results.

**Hepatic MT induction by ZnCl₂**

Treatment with a non-toxic dose of ZnCl₂ for 3 days resulted in a 100-fold increase of MT-1 mRNA expression and a 190-fold increase in MT-2 (Figure 5.1 A). No other gene quantified showed a significant change including
CuZnSOD, MnSOD, GPx1, catalase, HO-1, HSP70, TNF-α, IL-1β, IL-10, KC, MIP-2, iNOS or ICAM-1 (data not shown). Similar gene expression profiles were recently reported for the same dose of ZnCl₂ given over 4 days (Liu et al., 2009). The increase in MT mRNA translated into extensive MT protein expression, as indicated by western blot analysis (Figure 5.1 B) and immunohistochemical staining of liver sections (Figure 5.1 C).

*Hepatic MT induction protects against APAP toxicity.*

A dose of 300 mg/kg of APAP-induced severe liver injury at 6 h as indicated by the increase in plasma ALT activities and extensive liver necrosis (Figure 5.2, 5.3). Pretreatment with ZnCl₂ attenuated the increase in plasma ALT levels by 68% and reduced the area of necrosis by 62% compared to APAP alone (Figure 5.2, 5.3). A similar protective effect was observed at 24 h (data not shown). To investigate the mechanism of protection, liver sections were stained for nitrotyrosine protein adducts, which is an indicator of peroxynitrite formation, and the TUNEL assay, an indicator for nuclear DNA fragmentation. Whereas there was no nitrotyrosine or TUNEL staining in untreated controls (data not shown), extensive centrilobular areas stained positive for both nitrotyrosine and DNA fragmentation 6 h after APAP treatment (Figure 5.3). The staining correlated with the area of necrosis as assessed in H&E stained sections (Figure 5.3). Pretreatment with ZnCl₂ substantially reduced both nitrotyrosine staining and the number of TUNEL-positive cells (Figure 5.3). Because most peroxynitrite is being formed in mitochondria (Cover et al.,
2005b), these data suggest that MT induction either prevented the mitochondrial oxidant stress or scavenged peroxynitrite.

**MT induction prevents against APAP-induced oxidant stress.**

In a previous study, we demonstrated that ROS (mainly hydrogen peroxide) but not peroxynitrite was responsible for GSSG formation in the liver after APAP overdose (Knight et al., 2002). To assess whether MT can scavenge hydrogen peroxide *in vivo*, hepatic GSH and GSSG levels were measured in the liver (Figure 5.4). At 6 h after APAP treatment, total glutathione (GSH+GSSG) levels only partially recovered (Figure 5.4 A), the GSSG content was significantly increased (Figure 5.4 B) and the GSSG-to-GSH ratio was increased from 0.5% to 2.5% (Figure 5.4 C). The data indicate a significant oxidant stress in these livers consistent with previous reports that identified this GSSG increase as being predominantly in mitochondria (Jaeschke, 1990; Knight et al., 2001). Induction of MT with ZnCl₂ improved the recovery of hepatic GSH levels, attenuated the increase in GSSG content and significantly reduced the GSSG-to-GSH ratio (Figure 5.4 A-C). These results suggest that MT induction attenuated the formation of reactive oxygen species *in vivo* rather than scavenged them. To directly assess whether MT is able to scavenge reactive oxygen species in intact cells, isolated mouse hepatocytes were exposed to various concentrations of hydrogen peroxide (H₂O₂), the ROS most likely responsible for the elevated GSSG levels. H₂O₂ dose-dependently caused cell injury as indicated by LDH release (Figure 5.5...
A, B). However, pretreatment with ZnCl$_2$ did not affect the injury in normal cells. In contrast, prior depletion of GSH substantially aggravated H$_2$O$_2$–induced cell death (Figure 5.5 A, B). In agreement with these results, ZnCl$_2$–pretreatment did not affect cell injury in GSH-depleted hepatocytes (data not shown). Together these data suggest that intracellular GSH was able to detoxify H$_2$O$_2$ diffusing into the cell. However, intracellular MT expression did not impact ROS-mediated toxicity indicating that MT, in contrast to GSH, did not detoxify H$_2$O$_2$. Overall, the combined in vitro and in vivo data suggest that MT prevented APAP-induced ROS formation rather than scavenged ROS.

**MT induction did not affect NAPQI formation.**

The fact that MT induction prevented the oxidant stress indicates that MT must have acted upstream of mitochondria. To evaluate whether ZnCl$_2$ treatment affected NAPQI formation, the initial depletion kinetics of GSH was measured. During the first 20 min after APAP injection, the rapid decline of hepatic GSH levels is caused almost exclusively by NAPQI formation (Jaeschke, 1990). Controls and ZnCl$_2$–treated animals showed a similar rate of GSH loss during the first 20 min (Figure 5.6). However, livers from ZnCl$_2$–treated mice had significantly higher basal GSH levels than livers from control animals (Figure 5.6). The difference was maintained during the first 20 min and disappeared when GSH depletion in controls slowed down more rapidly compared to the ZnCl$_2$-treated animals (Figure 5.6). Together, these data suggest that NAPQI formation was not impaired by MT induction, but the
livers from ZnCl₂-treated animals had a higher capacity to detoxify NAPQI. The slightly higher GSH level may have been a contributing factor but was unlikely the only reason for the effective protection against APAP-induced liver injury.  

**MT can scavenge and covalently bind NAPQI.**

Because MT induction did not reduce NAPQI formation but prevented the mitochondrial oxidant stress, which is assumed to be caused by NAPQI binding to mitochondrial proteins, the only remaining intervention point could be the direct scavenging of NAPQI by MT. To test this hypothesis, a solution of purified MT (1 mg/ml) was mixed with NAPQI solution (12 µg/ml) at 4°C and transferred immediately or after 2 h of incubation at 4°C to the loop of an HPLC connected online to a mass spectrometer and analyzed as indicated in material and methods (Figure 5.7). As a control sample, an aliquot of MT kept under the same conditions, but without the addition of NAPQI, was analyzed under the identical conditions. This control sample showed multiple ions in the m/z range 1537-1566, corresponding to the +4 charge state of the protein (Figure 5.7 A). This is consistent with the presence of several isoforms of MT in the commercially available form of the protein. Mixing of MT with NAPQI resulted in the immediate disappearance of the ions at m/z range 1537-1566 with a time-dependent formation of a series of ions at a higher m/z range (1592-1644) (Figure 5.7 B). Four of these ions, at m/z at 1637.6, 1643.7, 1666.4 and 1671.7, are clearly newly formed. Other ions, at m/z at 1592.7,
1611.6 and 1618.3, appear on top of small ions present in the commercial preparation of MT. However, their relative change in intensity indicates that these ions are also the result of the reaction of NAPQI with MT. The dead time between the addition of NAPQI and the injection on the loop of the HPLC to start the chromatographic separation was 20 sec. This reaction is complete following 2 h incubation at 4°C (Figure 5.7 C). Because of the complexity of the resulting mass spectra, the exact pair of shifts in mass can not be determined with absolute certainty. However, given the accuracy of the mass measurement and the fact that the reaction of NAPQI with proteins results in an increase in mass of 149.1 Dalton (Hoos et al., 2007), it is possible to assume that most of the isoforms of MT reacted with one, two or three molecules of NAPQI, resulting in a shift of 149 Dalton (from m/z 1554.6 to m/z 1592.8), 298 Dalton (from m/z 1537.1, 1545.2, 1561.2 to 1565.6 to 1611.6, 1683.3, 1637.6 and 1643.7, respectively) or 447 Dalton (from m/z 1554.7 and 1561.2 to 1565.4 and 1671.6, respectively).

**MT induction is responsible for ZnCl₂-induced protection against APAP-induced hepatotoxicity.**

To verify that MT gene expression was indeed the mechanism by which Zn reduced APAP-induced liver injury, 129S1/SvImJ wildtype and MT-deficient mice were treated with APAP for 6 h. Based on plasma ALT activities and the area of necrosis, APAP caused severe liver injury, which was significantly attenuated in Zn-treated wildtype animals but not in MT-deficient mice (Figure
5.8). These data support the conclusion that MT gene expression is the main mechanism of protection of the Zn treatment regimen employed in this study.
Figure 5.1
Figure 5.1

Quantitative real-time PCR was used to analyze for MT-1 and MT-2 mRNA expression in livers of animals treated with saline (6 ml/kg) (controls, C) or 100 µmol/kg ZnCl$_2$ for 3 days. MT mRNA is expressed as the MT-to-actin ratio (A). Data represent mean ± SE of n = 4 animals *P<0.05 (compared to C). Western blot analysis of MT protein in controls and ZnCl$_2$-treated animals (B). Immunohistochemical analysis of MT expression in control liver compared to the liver of a ZnCl$_2$-treated animal (C).
Figure 5.2
Figure 5.2
Liver injury was evaluated by measuring plasma alanine aminotransferase (ALT) activities (panel A) and quantitating the area of necrosis (panel B) in untreated animals (C) and 6 h after injection of 300 mg/kg acetaminophen (APAP). Animals were either treated with saline (6 ml/kg) or 100 µmol/kg ZnCl₂ for 3 days. APAP was injected 24 h after the last dose of Zn/saline. Data represent means ± SE of n = 5 animals per group. *P<0.05 (compared to C) #P<0.05 (compared to APAP/saline)
Figure 5.3
Figure 5.3

Representative liver sections of animals treated for 6 h with 300 mg/kg acetaminophen were stained with H&E (assess area of necrosis), a nitrotyrosine antibody (marker of peroxynitrite formation) and the TUNEL assay (marker for DNA strandbreaks). Animals were either treated with saline (6 ml/kg) or 100 µmol/kg ZnCl2 for 3 days. APAP was injected 24 h after the last dose of Zn/saline. (magnification of all graphs: x50)
Figure 5.4
Figure 5.4
Total glutathione (GSH+GSSG) (panel A) and glutathione disulfide (GSSG) (panel B) levels were measured and the GSSG-to-GSH ratio (panel C) was calculated 6 h after treatment with 300 mg/kg APAP. Animals were either treated with saline (6 ml/kg) or 100 μmol/kg ZnCl₂ for 3 days. APAP was injected 24 h after the last dose of Zn/saline. Data represent means ± SE of n = 5 animals per group. *P<0.05 (Compared to APAP)
Figure 5.5
Figure 5.5
Primary cultured murine hepatocytes were exposed to various concentrations of hydrogen peroxide (H$_2$O$_2$) or vehicle (culture medium) for up to 4 h and cell injury was measured as % of released lactate dehydrogenase (LDH). Animals used for cell isolation were either untreated or received 100 µmol/kg ZnCl$_2$ for 3 days or 100 mg/kg phorone 90 min before isolation. All cells isolated from phorone-treated animals were cultured in the presence of 1 mM buthionine sulfoximine to inhibit GSH synthesis. All data represent means ± SE of 4 independent time course experiments. *P<0.05 (compared to H$_2$O$_2$ alone)
Figure 5.6
Figure 5.6

Hepatic glutathione levels (GSH+GSSG) were measured at early time points (0 – 40 min) after administration of 300 mg/kg acetaminophen. Animals were either treated with saline (6 ml/kg) or 100 µmol/kg ZnCl₂ for 3 days. APAP was injected 24 h after the last dose of Zn/saline. Data represent means ± SE of n = 5 animals per group. *P<0.05 (compared to controls)
Figure 5.7
Figure 5.7
Rabbit liver MT was analyzed by reverse phase chromatography/mass spectrometry as described in the experimental procedures. The figure shows the +4 charge state protein ions obtained on the IT of the control sample. An aliquot of MT that was not reacted with NAPQI (A), or following the addition of NAPQI and incubation at 4 °C for 20 sec (B) or 2h (C). For each panel, data are reported as percentage relative to the most intense ion. Thus, the progress of the reaction is indicated by a change in the relative intensities of the ions present at each experimental time. There is a decrease of the intensity of the ions in the m/z range 1537-1565 with a concomitant increase of the ions in the m/z range 1592-1671.
Figure 5.8
Figure 5.8

Liver injury was evaluated by measuring plasma alanine aminotransferase (ALT) activities (panel A) and quantitating the area of necrosis (panel B) in wildtype and MT-1/MT-2-deficient (MT KO) mice 6 h after injection of 300 mg/kg acetaminophen (APAP). Animals were either treated with saline (6 ml/kg) (S) or 100 µmol/kg ZnCl₂ for 3 days. APAP was injected 24 h after the last dose of Zn/saline. Data represent means ± SE of n = 4-6 animals per group. *P<0.05 (compared to APAP/saline)
Figure 5.9
Figure 5.9
See text for details. Abbreviations: AIF, apoptosis-inducing factor; EndoG, endonuclease G; GSSG, glutathione disulfide; MPT, mitochondrial membrane permeability transition pore; MT, metallothionein; NAPQI, N-acetyl-p-benzoquinone imine; NT adducts, nitrotyrosine protein adducts; ONOOH, peroxynitrite;
5.4 Discussion.

The objective of this investigation was to evaluate the mechanism(s) of protection of MT induction by ZnCl$_2$ against APAP hepatotoxicity. Our data support the conclusion that ZnCl$_2$ selectively induced MT gene expression, which did not scavenge reactive oxygen species but appeared to prevent the oxidant stress by scavenging the reactive metabolite NAPQI.

It is well established that heavy metals including Zn can induce MT gene expression in the liver (Klaassen et al., 1999; Liu et al., 2009). The present data confirmed this observation and showed that both MT-1 and MT-2 mRNA levels were induced in the liver and that this translated into a substantial increase in MT protein expression in hepatocytes. Despite the effective induction of MT by Zn, there is some controversy whether this is the main mechanism by which Zn can protect against drug-induced liver injury. For example, Zn supplementation in the diet attenuated alcoholic liver injury in MT-deficient mice during a 12-week study suggesting that the protection was independent of MT (Zhou et al., 2005). However, the average oral Zn intake was calculated to be 33 mg/kg/day (505 µmol/kg/day), which is about 5 times higher than the subcutaneous dose used in the present investigation for 3 days. A similar s.c. treatment of Zn did not protect MT-deficient mice against APAP-induced liver injury (Liu et al., 2009). We could confirm these findings (Figure 5.8) suggesting that MT induction was the principle mechanism of
protection. In addition, we showed that 100 µmol/kg/day ZnCl₂ selectively induced MT but did not affect a number of other genes, whose upregulation has been shown to be beneficial against APAP-induced liver injury. This includes HO-1 (Chiu et al., 2002), HSP70 (Tolson et al., 2006) and MnSOD (Fujimoto et al., 2009). A recent genomic study using the same dose of Zn reported similar findings (Liu et al., 2009). These data together suggest that the protective effect of ZnCl₂ treatment was mainly caused by MT induction in hepatocytes. However, the slightly higher hepatic GSH levels in ZnCl₂-treated animals may have also contributed to the protection. This effect of Zn could have been caused by the moderate upregulation of nuclear factor-erythroid 2-related factor 2 (Nrf2) (Liu et al., 2009), which positively regulates GSH synthesizing enzymes (Lu, 2009).

It has been extensively postulated that MT can scavenge reactive oxygen species (Kumari et al., 1998; Sato and Bremner, 1993; Thornalley and Vasak, 1985). However, most studies were done with isolated proteins in a test tube. In an in vivo study where it was concluded that MT protected against APAP toxicity by acting as ROS scavenger it remained unclear whether MT prevented formation of ROS or scavenged them (Liu et al., 1999). Our in vivo data demonstrated that MT induction reduced nitrotyrosine staining and prevented DNA fragmentation, which is dependent on mitochondrial peroxynitrite formation and dysfunction (Bajt et al., 2008; Cover et al., 2005b).
These results can be interpreted as if MT acted as an effective scavenger of peroxynitrite in the mitochondria or that MT acted upstream and prevented the formation of ROS. The fact that MT induction reduced hepatic GSSG levels and the GSSG-to-GSH ratio after APAP, suggests that the formation of ROS, especially hydrogen peroxide, was prevented. This conclusion is supported by previous findings showing that GSSG levels remained elevated when only peroxynitrite is scavenged, but ROS formation is unaffected (Knight et al., 2002). In addition, the experiments with isolated hepatocytes exposed to various concentrations of hydrogen peroxide did not indicate that MT was able to effectively scavenge ROS in the presence or absence of GSH. In contrast, GSH was the critical antioxidant controlling ROS-induced cell death in hepatocytes. This shows that hydrogen peroxide entered the cells and a competent scavenger (GSH) was able to intercept this oxidant in the cytosol. In general, peroxides diffuse into the cell, trigger mitochondrial dysfunction and ultimately cause MPT pore formation and cell necrosis (Nieminen et al., 1995). Although most MT is expressed in the cytosol after induction, MT did not affect cell injury. This indicates that MT is not a relevant scavenger of hydrogen peroxide, which suggests that the reduced hepatic GSSG levels and the reduced GSSG-to-GSH ratio in APAP-treated animals are unlikely to be caused by the scavenging of ROS, especially not in the presence of GSH. Thus, our findings indicate that MT acted upstream of the initiation of the mitochondrial oxidant stress.
The main event upstream of mitochondrial protein binding is the formation of the reactive metabolite NAPQI. Inhibition of the metabolic activation is most effective in preventing APAP toxicity. Because NAPQI is detoxified by GSH, the initial decline of the hepatic GSH levels reflects the formation of NAPQI (Jaeschke, 1990). Based on the GSH depletion kinetics, there was no relevant difference between controls and ZnCl$_2$-treated animals, suggesting that there was no difference in NAPQI formation. However, it was observed that the basal GSH levels after ZnCl$_2$ were higher than in controls. Although the difference was only 11%, the data indicate a slightly higher capacity to detoxify NAPQI in the ZnCl$_2$-treated livers. This effect may have contributed to the protective effect of ZnCl$_2$ treatment against APAP toxicity. Nevertheless, it is unlikely that this limited amount of additional GSH could have been entirely responsible for the protection against APAP toxicity.

The only remaining explanation for the protective effect of MT after NAPQI formation, but before mitochondrial protein binding, would be a direct scavenging of NAPQI by MT. Due to its high content of cysteine residues, MT can react with organic electrophiles (Cagen and Klaassen, 1980) including NAPQI (Roberts et al., 1987). Our mass spectrometric data confirm these findings and demonstrate directly a time-dependent covalent binding of 1-3 NAPQI molecules to each MT protein. Because the depletion kinetics of GSH is not affected, these data suggest that MT reacts with NAPQI only when GSH
levels are very low. A higher affinity of NAPQI to GSH as compared to the
sulfhydryl groups of MT has also been observed with other electrophiles
(Cagen and Klaassen, 1980). These findings indicate that MT induction is not
a primary detoxification mechanism for organic electrophiles, but MT can
become important once GSH is depleted as it is after APAP overdose.

In summary, we demonstrated that ZnCl$_2$ treatment effectively attenuated the
APAP-induced mitochondrial oxidant stress and peroxynitrite formation,
nuclear DNA damage and necrotic cell death (Figure 9). Because
MT-deficient mice were not affected by Zn treatment, the protective effect was
mainly caused by the induction of MT protein expression in hepatocytes. The
slightly higher GSH levels observed in ZnCl$_2$-treated animals may have also
contributed to the protection. The induction of MT did not affect the metabolic
activation of APAP but attenuated the oxidant stress. However, lower hepatic
GSSG levels after APAP and no evidence that MT was able to scavenge ROS
in vitro suggested a target upstream of mitochondria. MT was able to
effectively react with NAPQI once GSH was depleted. Thus, our data are
consistent with the conclusion that MT acts as a second line of defense
behind GSH to scavenge NAPQI and prevent the binding to cellular proteins
including mitochondrial proteins. This will attenuate the mitochondrial oxidant
stress and peroxynitrite formation, which are critical mediators of
APAP-induced liver injury. Because MT can be induced by various cellular
stresses it could be target for drug toxicity prophylaxis. As such, MT expression could also be an unrecognized mechanism of protection of certain interventions such as a neutropenia antibody (Jaeschke and Liu, 2007).
CHAPTER 6: ROLE OF C-JUN-N-TERMINAL KINASE IN ACETAMINOPHEN-INDUCED LIVER INJURY

6.1 Abstract

Acetaminophen (APAP) overdose, which causes liver injury in animals and humans, activates c-jun N-terminal kinase (JNK). Although it was shown that the JNK inhibitor SP600125 effectively reduced APAP-induced hepatotoxicity, the mechanisms of protection remain unclear. C57Bl/6 mice were treated with 10 mg/kg SP600125 or vehicle (8% dimethylsulfoxide) 1h before 600 mg/kg APAP administration. APAP time-dependently induced JNK activation (detected by JNK phosphorylation). SP600125, but not the vehicle, reduced JNK activation, attenuated mitochondrial Bax translocation and prevented the mitochondrial release of apoptosis-inducing factor at 4–12 h. Nuclear DNA fragmentation, nitrotyrosine staining, tissue GSSG levels and liver injury (plasma ALT release and necrosis) were partially attenuated by the vehicle (-65%) and completely eliminated by SP600125 (-98%) at 6 and 12h. Furthermore, SP600125 attenuated the increase of inducible nitric oxide synthase (iNOS) mRNA and protein. However, APAP did not enhance plasma nitrite+nitrate levels (NO formation); SP600125 had no effect on this parameter. The iNOS inhibitor L-Nil did not reduce NO formation or injury after APAP but prevented NO formation caused by endotoxin. Since SP600125 completely eliminated the increase in hepatic GSSG levels, an indicator of
mitochondrial oxidant stress, it is concluded that the inhibition of peroxynitrite was mainly caused by reduced superoxide formation. Our data suggest that the JNK inhibitor SP600125 protects against APAP-induced liver injury in part by attenuation of mitochondrial Bax translocation but mainly by preventing mitochondrial oxidant stress and peroxynitrite formation and thereby preventing the mitochondrial permeability transition pore opening, a key event in APAP-induced cell necrosis.

6.2 Introduction

An overdose of acetaminophen (APAP), a commonly used analgesic drug, can cause hepatic necrosis and even liver failure in humans and animals. APAP overdose is currently the most frequent cause of drug-induced liver failure in the US (Larson et al., 2005). APAP-induced liver cell injury is initiated by the formation of a reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI), which can be generated by several cytochrome P-450 isoenzymes, especially cyp2E1 (Nelson, 1990). NAPQI is detoxified by glutathione (GSH), resulting in the depletion of this sulphhydryl reagent (Mitchell et al., 1973). Once cellular GSH is consumed, NAPQI covalently binds to cellular proteins (Cohen et al., 1997). However, cell injury correlates less with total protein binding but more with the capacity to bind to mitochondrial proteins (Tirmenstein and Nelson, 1989). These findings support the hypothesis that covalent binding to mitochondrial proteins may be
responsible for mitochondrial dysfunction (Jaeschke and Bajt, 2006; Jaeschke et al., 2003). The well established effects of an APAP overdose on mitochondria include inhibition of mitochondrial respiration, enhanced formation of reactive oxygen species and peroxynitrite, mitochondrial DNA damage, release of mitochondrial intermembrane proteins, which translocate to the nucleus and cause nuclear DNA degradation, and ultimately opening of the mitochondrial membrane permeability transition pore with collapse of the membrane potential (Jaeschke and Bajt, 2006; Jaeschke et al., 2003).

C-jun-N-terminal kinase (JNK) is a member of the mitogen-activated protein kinase (MAPK) superfamily (Hibi et al., 1993). JNK can activate a variety of signal cascades through its phosphorylation of not only transcription factors such as c-jun (Li et al., 2004b), p53 (Cheng et al., 2003), and ATF-2 (Hayakawa et al., 2003), but also members of the Bcl-2 family (Latchoumycandane et al., 2007). JNK has 2 ubiquitously expressed isoforms (JNK1, JNK2) and a tissue-specific isoform (JNK3), which is predominately located in neurons of the central nervous system (Resnick and Fennell, 2004). JNK1 mediates the majority of c-jun phosphorylation and JNK2 mainly regulates c-jun stability (Sabapathy et al., 2004).

Studies with APAP overdose clearly demonstrated prolonged activation of JNK before cell death. Furthermore, pharmacological inhibition of JNK or
the silencing of JNK gene expression resulted in reduced liver injury after APAP overdose (Gunawan et al., 2006; Hanawa et al., 2008; Henderson et al., 2007). However, the use of JNK-deficient mice yielded mixed results. One study showed a partial protection with JNK2- but not JNK1-deficient mice (Gunawan et al., 2006). Other studies did not find a protection with either JNK knockout mice (Bourdi et al., 2008; Henderson et al., 2007). In contrast, one report suggested a beneficial role of JNK2 in tissue repair after APAP (Bourdi et al., 2008). Although apoptosis signal-regulating kinase 1 (ASK1), a member of the mitogen-activated protein kinase kinase kinase family, has been identified as the upstream activator of JNK (Nakagawa et al., 2008a), the downstream mechanisms by which JNK affects APAP hepatotoxicity are less clear. It was suggested that JNK may act by triggering Bax activation and translocation to the mitochondria (Gunawan et al., 2006). However, Bax-deficient mice are only temporarily protected against APAP-induced hepatotoxicity (Bajt et al., 2008) suggesting that additional mechanisms may be operative. More recently it was proposed that JNK is activated by reactive oxygen species generated by GSH-depleted mitochondria, which triggers the translocation of activated JNK to mitochondria resulting in the induction of the mitochondrial permeability transition (Hanawa et al., 2008). A caveat of this hypothesis is that reactive oxygen species have not been detected outside the mitochondria (Jaeschke, 1990) and that the more aggressive oxidant peroxynitrite, generated in mitochondria, was identified as a critical mediator
of the injury process (Cover et al., 2005b; Knight et al., 2002). A third mechanism, JNK-mediated activation of inducible nitric oxide synthase (iNOS), was also suggested (Latchoumycandane et al., 2007). However, inhibition of iNOS was not consistently beneficial in APAP hepatotoxicity (Gardner et al., 2003; Hinson et al., 2002). Therefore, our goal was to assess all three mechanisms simultaneously and evaluate by which mechanism the pharmacological and genetic inhibition of JNK protects in an in vivo murine model of APAP hepatotoxicity.
6.3 Results

Functional significance of JNK activation after APAP overdose: JNK2 KO Mice

For studying mechanisms of APAP-induced liver injury, the most frequently used dose by us and others is 300 mg/kg in overnight fasted animals (Cover et al., 2005a; Gardner et al., 2003; Hinson et al., 1998; Knight et al., 2002; Knight et al., 2001). This dose consistently causes severe liver injury in almost all mouse strains. Administration of 300 mg/kg APAP resulted in the activation of JNK in the livers of C57Bl/6 mice as indicated by the appearance of the phosphorylated form (P-JNK) with an early peak at 2 h and second peak at 6 h (Figure 1A). At 24 h, no P-JNK was detectable. The phosphorylation of both JNK isoforms (JNK1, 46 kDa; JNK2, 54 kDa) observed after APAP is consistent with previous reports (Bourdi et al., 2008; Hanawa et al., 2008; Henderson et al., 2007; Latchoumycandane et al., 2007; Nakagawa et al., 2008b). Delayed treatment with GSH, which effectively scavenged peroxynitrite and hydrogen peroxide (Knight et al., 2002) or treatment with ZnCl₂, which induced metallothionein and partially prevented the mitochondrial oxidant stress (Saito et al.) also prevented JNK activation (Figure 6.1B). These data suggest that JNK activation is linked to the formation of oxidant stress in this model. Both, the scavenging of reactive oxygen species by GSH administration and the partial prevention of mitochondrial oxidant stress by Zn pretreatment together with the inhibition of
JNK activation resulted in significantly reduced liver injury (Figure 6.2A). To directly evaluate the pathophysiological role of JNK, wild type and JNK2 KO mice were treated with 300 mg/kg APAP. At 6 h, plasma ALT levels increased to a similar degree in both WT and JNK2 KO mice (Figure 6.2B) reflecting severe centrilobular necrosis (Figure 6.2C). To confirm the findings with JNK2 KO mice, C57Bl/6 mice were treated with the general JNK inhibitor SP600125 or the vehicle DMSO/PBS. Although 300 mg/kg APAP alone caused severe liver injury at 6 h (plasma ALT: 5220 ± 1085 U/L), treatment with the vehicle alone or with SP600125 completely prevented any liver injury (data not shown). The reason for the complete protection by the vehicle alone is that the dose of DMSO (1.2 ml/kg) necessary to dissolve the inhibitor effectively blocks the metabolic activation of APAP (Jaeschke et al., 2006). Thus, a higher dose of APAP (600 mg/kg) had to be used to overcome this block (Hanawa et al., 2008).

**Functional significance of JNK activation after APAP overdose:**

**SP600125**

Treatment of C57Bl/6 mice with 600 mg/kg APAP resulted in a rapid loss of hepatic GSH content due to NAPQI formation (Figure 6.3). Within 20 min GSH levels decreased by 62% and within 2 h 92% was lost. However, pretreatment with SP600125 or its vehicle substantially delayed the initial decline, but GSH levels had fallen by 81-88% by 2 h (Figure 6.3). These data
indicate that the high dose of APAP overcame some of the inhibition of the metabolic activation in the presence of DMSO. To evaluate the functional significance of JNK, the effect of SP600125 on liver injury was evaluated at 6 and 12 h after APAP (Figure 6.4 A,B). Compared to PBS-treated animals, the DMSO-containing vehicle substantially attenuated liver injury at both time-points as reflected by the approximately 65% reduction in ALT release at both time points (Figure 6.4A) and the reduced area of necrosis at 12 h (Figure 6.4B). However, liver injury was essentially completely prevented by pretreatment with SP600125 (Figure 6.4A,B). These findings were confirmed by using the TUNEL assay to evaluate nuclear DNA damage (Figure 6.4C). Previous reports from our laboratory provided evidence for the translocation of mitochondrial intermembrane proteins such as apoptosis-inducing factor (AIF) and endonuclease G to the nucleus as the main cause of the nuclear DNA damage after APAP overdose (Bajt et al., 2006). This effect was caused initially by formation of Bax pores in the outer membrane and subsequently by mitochondrial swelling and rupture of the outer membrane due to MPT (Bajt et al., 2008). In support of these events, JNK activation, release of AIF into the cytosol and translocation of Bax to the mitochondria was observed 12 h after APAP (Figure 6.5). Although the vehicle was without effect on these parameters, SP600125 effectively reduced JNK activation, mitochondrial AIF release and mitochondrial Bax translocation (Figure 6.5). To confirm that these events are not just consequences of the protection observed at 12 h,
the same parameters were also measured at an earlier time point (4 h) where only minimal injury occurred (Figure 6.6). Again, APAP caused JNK activation, mitochondrial Bax translocation and release of AIF, all of which were effectively attenuated by SP600125 (Figure 6.6). The vehicle DMSO partially prevented mitochondrial AIF release but had no relevant effect on JNK activation and mitochondrial Bax translocation (Figure 6.6). Together these data support the conclusion that JNK activation causes mitochondrial Bax translocation, which is responsible for the initial AIF and endonuclease G release from the mitochondria and early nuclear DNA damage. However, studies with Bax-deficient mice showed no effect of Bax on the mitochondrial oxidant stress and peroxynitrite formation, which ultimately were responsible for the later release of AIF and endonuclease G and the resulting DNA degradation and cell death (Bajt et al., 2008). Since SP600125 effectively prevented cell death even at later time points, these data suggest that JNK has additional, more critical effects than just causing Bax activation.

Effect of SP600125 on iNOS expression and peroxynitrite formation

It is well established that APAP overdose causes peroxynitrite formation in cells undergoing necrotic cell death (Hinson et al., 1998; Knight et al., 2001). To evaluate if JNK activation is associated with peroxynitrite formation, liver tissue was stained for nitrotyrosine protein adducts (Figure 6.7). APAP overdose caused substantial peroxynitrite formation in centrilobular
hepatocytes at 6 h (Figure 6.7) and at 12 h (data not shown). Pretreatment with the vehicle DMSO partially reduced, whereas treatment with SP600125 completely eliminated, nitrotyrosine staining at both 4 and 12 h (Figure 6.7). These data suggest that JNK activation is involved in peroxynitrite formation. Since it was previously hypothesized that JNK activation may enhance liver injury by promoting peroxynitrite formation through iNOS induction (Latchoumycandane et al., 2007), the effect of APAP and JNK on iNOS was investigated. APAP overdose caused a 3.5-fold and a 7-fold increase of iNOS mRNA at 4 and 12 h, respectively (Figure 6.8A). This translated into a minor increase in iNOS protein expression at 6 h (Figure 6.8B) and at 12 h (data not shown). However, plasma nitrite + nitrate levels as indicators of NO formation did not change significantly (Figure 6.8C). Although SP600125 attenuated iNOS mRNA and protein levels, there was no significant effect on plasma nitrite + nitrate concentrations (Figure 6.8). In addition, the iNOS inhibitor L-Nil, affected neither plasma nitrite + nitrate levels (Figure 6.8C) nor APAP-induced liver injury (Figure 6.8D). As a positive control, LPS treatment substantially enhanced plasma nitrite + nitrate concentrations, which were reduced to baseline by L-Nil treatment (Figure 6.8C). Although these data confirm that JNK was involved in a minor transcriptional induction of iNOS after APAP overdose, the beneficial effect of inhibiting JNK activation on peroxynitrite formation and liver injury was independent of iNOS.

**Role of JNK in APAP-induced mitochondrial oxidant stress**
Since APAP-induced peroxynitrite formation did not appear to be caused by JNK-mediated enhanced NO generation, especially from iNOS, formation of reactive oxygen was assessed. It was previously demonstrated that increased tissue levels of GSSG after APAP reflect mainly mitochondrial superoxide/hydrogen peroxide but not peroxynitrite formation (Jaeschke, 1990; Knight and Jaeschke, 2004; Knight et al., 2001). Thus, GSH and GSSG levels were measured at 12 h after APAP (Figure 6.9). The total hepatic glutathione content (GSH+GSSG) was still partially depleted after treatment with APAP alone but GSSG levels were significantly elevated above controls (Figure 6.9A,B). This resulted in an increased GSSG-to-GSH ratio from less than 0.5 to more than 2.5 (Figure 6.9C). The vehicle-treated group, which was partially protected against APAP-induced liver injury (Figure 6.4), showed higher total glutathione and GSSG levels resulting in a significantly elevated GSSG-to-GSH ratio (Figure 6.9). These data indicate that the vehicle DMSO accelerated the recovery of liver GSH levels and improved the detoxification of reactive oxygen species but did not prevent the APAP-induced oxidant stress. In contrast, the JNK inhibitor SP600125 did not only promote the faster recovery of the hepatic GSH content, it completely prevented the increase in GSSG levels and the change in the GSSG-to-GSH ratio (Figure 6.9). These data are consistent with the conclusion that the JNK inhibitor completely prevented the APAP-induced oxidant stress.
Late treatment with GSH inhibits JNK activation

It was previously shown that delayed treatment with GSH up to 2.5 h protects against APAP hepatotoxicity by stimulating hepatic GSH synthesis and replenishing mitochondrial GSH levels, which scavenge reactive oxygen and peroxynitrite, as well as support the mitochondrial energy metabolism (Knight et al., 2002; Saito et al., 2009). Treatment with GSH 4 h after APAP enhanced hepatic GSH levels (Figure 6.10C) and strongly reduced JNK activation at 6 h in the APAP and the APAP/DMSO group (Figure 6.10A). SP600125 treatment alone prevented JNK activation and GSH administration did not affect these results despite inducing the highest GSH levels (Figure 6.10). Interestingly, DMSO did not affect JNK activation but reduced plasma ALT values by 71% (Figure 6.10B). In addition, delayed GSH treatment significantly reduced liver injury in the APAP group by 62% and in the APAP/DMSO group by 60% (Figure 6.10B). Despite a similar degree of low P-JNK expression in 4 groups, there were substantial differences in injury between the groups. These data suggest that scavenging mitochondrial reactive oxygen and peroxynitrite attenuates JNK activation and reduces APAP-induced liver injury.
Figure 6.1
Figure 6.1

JNK activation in response to treatment with 300 mg/kg acetaminophen (APAP). A. Time course of P-JNK formation as indicator of JNK activation in response to APAP treatment. β-actin protein expression is shown as loading control. B. Total JNK and P-JNK protein expression were measured in untreated controls (C) and in animals treated with 300 mg/kg APAP alone or together with either 0.65 mmol/kg GSH (i.v.) administered at 1.5 h after APAP or 100 µmol/kg ZnCl₂ administered for 3 days as described in details in the methods section.
Figure 6.2
Plasma alanine aminotransferase (ALT) activities as an indicator for APAP-induced hepatotoxicity were measured in C57BL/6 mice 6 h after 300 mg/kg APAP administration. A. Animals were either untreated (C) or received APAP alone or together with GSH at 1.5 h after APAP or with 100 µmol/kg ZnCl₂. Data represent means ± SE of n = 4 animals per group. *P<0.05 (compared to C), #P<0.05 (compared to APAP). B. Plasma ALT activities were measured in wild type and JNK2-deficient (JNK2 KO) mice 6 h after injection of 300 mg/kg APAP. Data represent means ± SE of n = 4 animals per group. *P<0.05 (compared to untreated controls). C. Representative liver sections of animals treated for 6 h with 300 mg/kg APAP were stained with H&E (assess area of necrosis) (C). (x50 for all panels).
Figure 6.3
Figure 6.3

The liver content of total glutathione (GSH + GSSG) was determined in untreated controls (C) or 20 min or 2 h after injection of APAP (600 mg/kg, ip). Some of the animals were pretreated with either 15 ml/kg PBS, 15 ml/kg DMSO (8.3% in PBS) or SP600125 (10 mg/kg in DMSO/PBS). Data represent means ± SE of n = 4 animals per group. *P<0.05 (compared to C) #P<0.05 (compared to APAP- PBS).
Figure 6.4
Figure 6.4

A. Plasma ALT activities were measured in untreated controls (C) and at 6 or 12 h after administration of 600 mg/kg APAP in mice with either 15 ml/kg PBS, 15 ml/kg DMSO in PBS or 10 mg/kg of the JNK inhibitor SP600125 at 1 h before APAP. Data represent means ± SE of n= 4-6 animals per group. *P<0.05 (compared to C), #P<0.05 (compared to APAP-PBS) and $P<0.05 (compared to DMSO). B. Histological assessment of liver injury in representative H&E-stained tissue sections obtained 12 h after APAP administration. C. DNA fragmentation was evaluated by the TUNEL assay in animals treated with 600 mg/kg APAP for 12h. (x50 for all panels).
Figure 6.5
Figure 6.5

P-JNK and JNK protein expression were determined in whole liver homogenates by Western blot analysis in untreated controls or at 12 h after APAP (600 mg/kg). The APAP-treated animals received either 15 ml/kg PBS, 15 ml/kg DMSO/PBS or 10 mg/kg of the JNK inhibitor SP600125 in DMSO/PBS. B. Apoptosis-induced factor (AIF) and Bax protein levels were determined by Western blot analysis in the cytosol and mitochondria, respectively, from animals treated with APAP and PBS, DMSO or SP600125 as described under A.
Figure 6.6
Figure 6.6

P-JNK in whole liver, AIF in cytosol and Bax in mitochondria were measured by Western blot analysis at 4 h after APAP (600 mg/kg). Some animals received PBS, DMSO or SP600125 1 h before APAP administration.
Figure 6.7
Figure 6.7
Nitrotyrosine staining as indicator of peroxynitrite formation in mice treated with 600 mg/kg APAP for 6 h or 12 h. Some of the animals received PBS, DMSO or the JNK inhibitor SP600125 at 1 h before APAP administration. One group of animals was treated with the iNOS inhibitor L-N-(1-iminoethyl)lysine (L-Nil; 3.3 mg/kg) at 0 and 3 h after APAP.
Figure 6.8
Figure 6.8

A. Hepatic iNOS mRNA expression was measured by real time RT-PCR in mice at 4 h and 12 h after 600 mg/kg APAP treatment. Data are expressed as the iNOS-to-actin mRNA ratio; the value of untreated control animals was set as 1. Some of the animals received 15 ml/kg PBS, 15 ml/kg DMSO/PBS or 10 mg/kg SP600125 in DMSO/PBS at 1 h before APAP administration. Data represent means ± SE of n = 3 animals per group. *P<0.05 (compared to C), #P<0.05 (compared to APAP/PBS).

B. Western blot analysis of iNOS expression in livers of controls or animals treated with 600 mg/kg APAP for 6 h. One to three representative samples are shown from each group. The numbers under the blot show the results of the densitometric analysis. Data of control animals were set as 1.

C. Plasma nitrate plus nitrite, which were used as a marker of NO production, and D. plasma ALT activities were measured at 6 h after 600 mg/kg APAP or 2 mg/kg lipopolysaccharide (LPS). Some of the animals received 15 ml/kg PBS (P), 15 ml/kg DMSO (8.3% in PBS) (D) or 10 mg/kg SP600125 in DMSO/PBS (SP) at 1 h before APAP administration. An additional group was treated with 3.3 mg/kg of the iNOS inhibitor L-N-(1-iminoethyl)lysine (NIL) at 0 and 3 h after APAP or LPS administration. Data represent means ± SE of n= 3-4 animals per group. *P<0.05 (compared to C), #P<0.05 (compared to P).
Figure 6.9
Figure 6.9

Hepatic content of total GSH (GSH + GSSG) (Panel A) and GSSG (Panel B) were measured in untreated controls (C) and in animals treated with 600 mg/kg APAP for 12 h. In addition, the GSSG-to-GSH ratio (Panel C) was calculated from each animal. Some of the animals received 15 ml/kg PBS (P), 15 ml/kg DMSO (8.3% in PBS) (D) or 10 mg/kg SP600125 in DMSO/PBS (SP) at 1 h before APAP administration. Data represent means ± SE of n = 4 animals per group. *P<0.05 (compared to C), #P<0.05 (compared to P).
Figure 6.10
Figure 6.10

P-JNK and β-actin protein expression (Panel A), plasma ALT activities (Panel B), and hepatic total glutathione content (GSH+GSSG) (Panel C) were measured at 6 h after 600 mg/kg APAP. Some of the animals received 15 ml/kg PBS (P), 15 ml/kg DMSO (8.3% in PBS) (D) or 10 mg/kg SP600125 in DMSO/PBS (SP) at 1 h before APAP administration. Additionally, some animals received 0.65 mmol/kg GSH (i.v.) 4 h after APAP administration.
Figure 6.11
Figure 6.11
Mechanisms of protection by JNK inhibitor against APAP-induced hepatotoxicity.
6.4 Discussion

*Protection against APAP hepatotoxicity by JNK inhibition.*

The main goal of this study was to evaluate the relative importance of several potential mechanisms of the involvement of JNK signaling in APAP-induced liver injury. JNK activation was monitored by formation of P-JNK due to the autophosphorylation of JNK during activation and the fact that JNK can phosphorylate a variety of downstream proteins not always to the same degree (Wicovsky *et al.*, 2007). Overall, our data showing JNK activation after APAP overdose and a protective effect with the specific JNK inhibitor SP600125 are in agreement with several previous studies (Gunawan *et al.*, 2006; Hanawa *et al.*, 2008; Henderson *et al.*, 2007; Latchoumycandane *et al.*, 2007). Furthermore, the importance of JNK in APAP-induced liver injury was demonstrated by the elimination of ASK, an upstream activator of JNK (Nakagawa *et al.*, 2008b). Our studies also support the conclusion that in contrast to the earlier report (Gunawan *et al.*, 2006) inhibition of JNK2 alone is not effective in reducing APAP hepatotoxicity (Bourdi *et al.*, 2008; Hanawa *et al.*, 2008; Henderson *et al.*, 2007). In addition, selective elimination of JNK1 was also ineffective (Bourdi *et al.*, 2008; Gunawan *et al.*, 2006; Henderson *et al.*, 2007). However, we did not observe an increase in APAP-induced liver injury at the 6 h time point using JNK2/- mice as was reported by Bourdi et al. for 12 -32 h after APAP (Bourdi *et al.*, 2008). Another important observation in our study is the fact that the solvent used to administer SP600125 (DMSO in
PBS) clearly inhibits the early metabolic activation of APAP and accounts for a substantial protection in this model. Although the inhibitor provides a significant additional effect, it cannot be excluded that the high efficacy of SP600125 may involve some solvent effect. However, since a peptide inhibitor of JNK in the absence of DMSO showed similar efficacy as SP600125 (Henderson et al., 2007), the effect is predominantly caused by inhibition of JNK rather than the initial inhibition of the metabolism.

**JNK activation and Bax translocation.** Our data indicate that inhibition of JNK reduces the mitochondrial translocation of Bax and the release of AIF from the mitochondria at early and late time points after APAP administration. The effect of JNK on Bax is in agreement with previous reports (Gunawan et al., 2006; Hanawa et al., 2008). We have previously shown that mitochondrial Bax translocation is an early event (beginning at 1 h) after APAP overdose, which is responsible for the early release of intermembrane proteins (Bajt et al., 2008; Jaeschke and Bajt, 2006). Although the release of cytochrome c and Smac does not result in activation of caspases (Knight and Jaeschke, 2002), the nuclear translocation of AIF and endonuclease G appears to be mainly responsible for the characteristic nuclear DNA fragmentation observed after APAP (Bajt et al., 2006). Since Bax-deficient mice show a strong reduction of intermembrane protein release, nuclear DNA damage and cell injury, it can be concluded that these Bax-mediated events contribute to cell
death at these early time-points (Bajt et al., 2008). However, mitochondrial Bax translocation does not affect the mitochondrial oxidant stress and peroxynitrite formation, which subsequently will trigger MPT resulting in mitochondrial swelling and rupture of the outer membrane (Bajt et al., 2008). At this later time-point, intermembrane proteins are released independent of Bax. Thus, even complete elimination of Bax results only in a temporary protection against APAP overdose. This means that the protective effect of JNK inhibition, which lasts during the first 12-24 h, can at best be mediated in part by inhibiting mitochondrial Bax translocation.

The possibility that JNK activation leads to inactivation of the protective Bcl-2 family members Bcl-2 and Bcl-x\textsubscript{L} by phosphorylation could also contribute to the mitochondrial dysfunction (Latchoumycandane et al., 2007). However, the protective role of Bcl-2 in APAP hepatotoxicity has been questioned as Bcl-2 overexpressing mice show actually higher injury compared to wild type animals (Adams et al., 2001). Other mechanisms suggested by which inhibition of JNK activation could be protective include the inhibition of Bid processing by caspase-8 inactivation (Wang et al., 2006) and downregulation of Bad expression (Takamura et al., 2007). However, this appears to be a mechanism mainly relevant for TNF-mediated apoptosis. Although not all of the individual Bcl-2 family members have been assessed in the APAP model, Bid-deficient mice are not protected (H. Jaeschke and X.M. Yin, unpublished)
and pancaspase inhibitors do not prevent mitochondrial dysfunction and liver injury after APAP (Jaeschke et al., 2006; Lawson et al., 1999) suggesting that potential effects of JNK on caspase-8 activation and Bid may not be relevant for the injury process.

**JNK activation and iNOS induction.**

Peroxynitrite, which is formed by the combination of the two radical species superoxide and nitric oxide (NO), is generated in cells undergoing necrosis during APAP hepatotoxicity (Hinson et al., 1998). Scavenging of this aggressive oxidant and nitrating agent by GSH resulted in a profound protection and improved regeneration (Bajt et al., 2003; Knight et al., 2002). However, the source of NO is still controversial. An induction of iNOS during APAP-induced liver injury has been reported (Gardner et al., 2002; Latchoumycandane et al., 2007) but peroxynitrite formation in the absence of iNOS induction was also observed (Knight et al., 2001). In the current study we found a relevant increase of iNOS mRNA but only a moderate increase in iNOS protein expression. Furthermore, no significant elevation of plasma nitrite+nitrate levels as indicator of actual NO formation was found. The potent iNOS inhibitor L-Nil (Zhang et al., 2000a), which completely prevented the endotoxin-induced increase in plasma nitrite+nitrate levels, had no effect on the formation of NO or peroxynitrite during APAP hepatotoxicity and did not affect liver injury. These data do not support the hypothesis that iNOS-derived
NO is critical for APAP-induced peroxynitrite formation and liver injury under our present conditions. A potential reason for the limited importance of iNOS during APAP-induced liver injury may be the formation of IL-10, which can suppress pro-inflammatory gene expression including iNOS thereby reducing a potential contribution of iNOS to the pathophysiology (Bourdi et al., 2002). Although SP600125 attenuated iNOS mRNA and also the minor increase in protein expression, there was no effect on plasma nitrite+nitrate levels. Together these data suggest that JNK activation may contribute to a limited iNOS induction during APAP hepatotoxicity. However, consistent with previous data of us and others (Hinson et al., 2002; Knight et al., 2001), iNOS did not play a relevant role and therefore it is unlikely that the profound protective effect of JNK inhibition was mediated by effects on iNOS. These conclusions are different than those of Latchoumycandane et al. (Latchoumycandane et al., 2007). However, these investigators used leflonamide, which may have additional effects beyond just inhibiting JNK.

**JNK activation and oxidant stress.**

Our previous studies with APAP hepatotoxicity documented the presence of a mitochondrial oxidant stress (Jaeschke, 1990; Knight et al., 2001) and mitochondrial peroxynitrite formation (Cover et al., 2005b), which preceded cell death and occurred as soon as GSH was depleted (Bajt et al., 2004). Furthermore, when peroxynitrite was being scavenged and more ROS was
detoxified by accelerated recovery of mitochondrial GSH levels initiated by treatment with GSH (Knight et al., 2002), JNK activation was prevented (Figure 6.1). Likewise, when the mitochondrial oxidant stress is inhibited by scavenging of NAPQI by metallothionein induction (Saito et al.), JNK activation was prevented (Figure 6.1). These findings suggest that in agreement with previous findings (Hanawa et al., 2008), an oxidant stress was the main trigger of JNK activation after APAP overdose. The oxidant stress most likely does not activate JNK directly but targets upstream events such promoting the dissociation of thioredoxin and apoptosis signal-regulating kinase 1 (ASK1) (Nakagawa et al., 2008a) or the Ras pathway (Saha and Nandi, 2009). Alternatively, JNK can be released from a complex with GST-Pi by binding of NAPQI to GST (Elsby et al., 2003). This would be in agreement with AMAP treatment not activating JNK (Hanawa et al., 2008) and the fact that JNK activation occurs in the cytosol and oxidant stress occurs mainly in mitochondria.

Although JNK appears to be activated by the initial oxidant stress, given the fact that nitrotyrosine staining of the tissue was eliminated by the JNK inhibitor at 6 and 12 h after APAP and that there was no increase of tissue GSSG or the GSSG-to-GSH ratio, it can be concluded that SP600125 effectively prevented the formation of reactive oxygen species. Since ROS and peroxynitrite are mainly formed in mitochondria, this suggested that JNK
activation promotes the formation of ROS in this cell organelle. Interestingly, the solvent of the JNK inhibitor (DMSO in PBS) did not prevent the oxidant stress (judged by GSSG formation) but appears to allow a faster recovery of hepatic GSH levels, which seem to scavenge most of the ROS and peroxynitrite and thus reduce tissue injury. The effect of DMSO is attributed to its inhibitory effect on APAP activation, which limits the injury and promotes recovery. Nevertheless, the JNK inhibitor clearly has additional effects that prevent the mitochondrial oxidant stress. Hanawa et al proposed that translocation of activated JNK may induce MPT (Hanawa et al., 2008). Given the time sequence of rapid GSH depletion and mitochondrial dysfunction followed by oxidant stress, eventually MPT and then cell necrosis (Bajt et al., 2004; Kon et al., 2004), it appears that JNK activation enhances the oxidant stress and peroxynitrite formation, which subsequently induces MPT. Mitochondrial oxidant stress is a potent inducer of MPT (Nieminen et al., 1997). This does not exclude that JNK can synergistically promote MPT through acting directly on proteins involved in MPT (Hanawa et al., 2008). However, it appears highly unlikely that JNK inhibition can prevent MPT in the presence of a substantial mitochondrial oxidant stress and peroxynitrite formation. Further studies are necessary to identify the various targets of JNK in the mitochondria.

In summary, JNK activation seems to control, at least in part, the early release
of intermembrane proteins and DNA fragmentation through mitochondrial Bax translocation. However, the most important effect of JNK activation was a profound suppression of peroxynitrite formation, which was not caused by inhibition of iNOS induction. In contrast, there was clearly a complete elimination of the mitochondrial oxidant stress. Although the exact target of JNK in the mitochondria has to be identified, it appears to be upstream of MPT.

Because of the critical role of oxidant stress and peroxynitrite for the propagation of the cell injury mechanisms, especially mitochondrial viability, (Figure 6.11) these data demonstrate that JNK could be an important target to limit cell injury and liver failure at least during the first 24 h after APAP overdose.
CHAPTER 7: CONCLUSION and CLINICAL RELEVANCY

APAP-induced hepatotoxicity in patients undergoes

In England and Wales, there are over 30,000 hospital admissions and about 150 deaths because of APAP overdose each year (Morgan et al., 2007). In the USA, acetaminophen-associated overdoses result in 56,000 emergency room visits, 26,000 hospital admissions, and about 450 deaths annually (Nourjah et al., 2006). Clinically, there are two causes of APAP overdose in patients including unintentional overdose and attempted suicide. In many cases of unintentional APAP ingestion, people are using alcohol, hypnotics, or illicit drugs in combination with APAP and often are unaware of the risk of delaying hospitalization. On the other hand, most intentional overdose patients receive medical care within 24 hours of APAP overdose. Unintentional overdoses are more frequent than intentional overdoses with the median dose being 34 g versus 20 g respectively, but these large doses are consumed over an average of 3 days. Once acute liver failure develops, the outcome for suicidal or unintentional APAP ingestion is similar (Lee, 2004).

The antidote for APAP poising is N-acetylcysteine (NAC), which is a cysteine prodrug, and a GSH precursor. Although NAC and cysteine are very similar in terms of chemical structure, NAC is less toxic, because it is less susceptible to oxidation and it is more soluble in water, which makes it a better source of cysteine than administration of cysteine itself (Atkuri et al., 2007). In the clinic,
NAC is injected as follows: one loading dose of 150 mg/kg followed by maintenance doses of 50 mg/kg every 4 h (Polson and Lee, 2005). Oral NAC administration frequently exacerbates the nausea and vomiting associated with APAP poisoning itself since the sulfur moiety of NAC gives a “rotten egg” smell. In 2004, the Food and Drug Administration approved an intravenous NAC administration, Acetadote® which is manufactured by Cumberland Pharmaceuticals in Nashville, Tennessee (Whyte et al., 2008). Intravenous administration of NAC was associated with reduction of antiemetic effects and cost saving (Miller et al., 2007).

**Summary and Conclusion**

We investigated three mechanisms of protection against APAP-induced hepatotoxicity in this thesis (Figure 7.1) and the following discussion focuses on the relevance of the conclusions to the clinical situation.
Figure 7.1
Mechanisms of protection in APAP-induced hepatotoxicity

a) Mechanism of protection A: preventing NAPQI binding to proteins

It is well known that the most effective mechanism of protection by GSH or NAC is to enhance the scavenging capacity for NAPQI in hepatocytes. This prevents modification of mitochondrial proteins and thereby blocks the
initiation of APAP toxicity. However, a limitation of this approach in the clinical scenario is that GSH or NAC must be administered during the time when APAP is being metabolized to NAPQI. By the time APAP overdose patients arrive at the emergency room, the metabolism of APAP is over in most cases. In aim 2, we demonstrated that zinc induced metallothionein (MT) can scavenge some of the excess NAPQI after GSH depletion thereby preventing covalent binding to cellular proteins. There are various stimuli to induce MT, such as restriction of food intake (Bremner and Davies, 1975), exercise (Oh et al., 1978; Shiraishi et al., 1983) in addition to heavy metal, and chemical induced MT. Therefore, a non-toxic intervention that induces MT might be beneficial for APAP overdose patients.

b) Mechanism of protection B: scavenging of reactive oxygen and peroxynitrite
Covalent binding of NAPQI to mitochondrial proteins leads to inhibition of mitochondrial respiration with increased mitochondrial synthesis of reactive oxygen species and peroxynitrite formation in mitochondria (Cover et al., 2005b; Jaeschke, 1990; Knight et al., 2001; Tirmenstein and Nelson, 1990). The resulting oxidant stress can activate the c-jun N-terminal kinase, which translocates to the mitochondria and may be involved in the further aggregation of ROS formation and induction of the mitochondrial membrane permeability transition pore opening (Hanawa et al., 2008).
In aim 3, we found that a JNK inhibitor suppressed peroxynitrite formation, which was not caused by inhibition of iNOS induction. However, there was clearly a complete elimination of the mitochondrial oxidant stress. It is probable that JNK could phosphorylate some of the proteins that are important for respiration in the mitochondria and inhibit mitochondrial function. This might also lead to accumulation of electrons and cause oxidative stress in mitochondria. In fact, it has been reported that JNK phosphorylated proteins have been implicated in the induction of mitochondrial membrane permeability pore in the rat brain (Schroeter et al., 2003). In addition, JNK inhibition can protect against APAP-induced disturbance of state III respiration (Hanawa et al., 2008). Although further research is required to determine the detailed mechanisms, JNK inhibitor may be a promising approach because it targets a critical toxic mechanism (ROS formation). In our experience, only interventions that target the mitochondria oxidative stress can be successful in preventing cell death. In addition, SP600125 was shown to be effective even several hours after APAP overdose (Gunawan et al., 2006; Hanawa et al., 2008; Henderson et al., 2007; Latchoumycandane et al., 2007).

c) Mechanism of protection C: Mitochondrial energy substrates

In the 1970s, NAC was used to treat patients with APAP overdose (Prescott et al., 1977). Even today, NAC therapy is thought to be the best treatment for overdose patients (Polson and Lee, 2005). However, our data from aim 1
indicates that GSH confers more efficient protection when compared to an equimolar dose of NAC. This effect is clearly caused by the 3-fold higher amount of amino acids in GSH compared to NAC, and we demonstrated that excess amino acids for metabolism in the Krebs cycle provide the most effective reduction of APAP-induced liver injury. Therefore, in addition to NAC to promote GSH synthesis, the administration of substrates to support the mitochondrial energy metabolism could be a promising supportive strategy to limit APAP-induced cell death and liver failure.
CHAPTER 8: REFERENCES CITED


Bourdi, M., Masubuchi, Y., Reilly, T. P., Amouzadeh, H. R., Martin, J. L.,


Ishida, Y., Kondo, T., Tsuneyama, K., Lu, P., Takayasu, T., and Mukaida, N.


Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., and


Comparative characterization of rat deoxyribonuclease 1 (Dnase1) and murine deoxyribonuclease 1-like 3 (Dnase1l3). *Biochem. J.* **389**, 355-64.


Invest. 116, 2280-2289.
